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External Assessment Centre report 
The purpose of the External Assessment Centre (EAC) report is to review and 
critically evaluate the sponsor’s clinical and economic evidence and may 
include additional analysis of the submitted evidence or new clinical and/or 
economic evidence.  
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1 Summary 
Scope of the sponsor’s submission  
The sponsor’s submission contained all published evidence available on the Urolift device, 
which comprised of  uncontrolled before and after studies, or reports of a single sham-
controlled, blinded RCT. The completeness of the sponsor’s evidence submission was 
confirmed by an independent EAC literature search. However, the NICE scope called for 
evidence that included TURP or HoLEP as a comparator and this evidence does not currently 
exist. 
Summary of clinical evidence submitted by the sponsor 
The sponsor submitted a peer-reviewed systematic review by Perera et al. (2014) in place of 
a de novo evidence submission and synthesis. The meta-analysis within Perera et al. (2014) 
utilizes data from 10 studies on IPSS score, men’s sexual health scores, health-related 
quality of life, urinary flow rate and post-void residual volume. Of the studies used in the 
systematic review, there were 2 published papers (McVary et al., 2014 & Roehrborn et al.,  
2013)  on a blinded, sham controlled RCT (LIFT Study), and 8 uncontrolled before and after 
studies (Abad et al., 2013; Cantwell et al., 2014; Chin et al., 2012; Delongchamps et al.,  
2012; McNicholas et al., 2013; Shore et al., 2014 & Woo et al., 2011 & 2012) . 
 The meta-analysis reported pooled estimates of outcome measures at 1, 3, 6 and 12 
months post-Urolift procedure. Results were shown as standardised mean gains (SMGs) 
rather than keeping the original units e.g. score for IPSS, ml/s for Qmax. Prostate symptom 
scores (IPSS and BPHII) are pooled and reported together, as are the sexual health scores 
IIEF, MSHQ-EjD and MSHQ-Bother. IPSS QoL is reported separately, as are Qmax and post-
void residual volume (PVR). All are reported with an effect size, and a heterogeneity score. 
The pooled IPSS/BPHII results presented indicate a large improvement in symptoms. The 
authors convert their reported SMGs into IPSS improvements as follows: -7.2 points (95% CI, 
-7.9 to -6.5) at 1 month, -8.3 (95% CI, -9.1 to -7.5) at 3 months, -8.7 (95% CI, -9.4 to -7.9) at 6 
months and -8.0 (95% CI, -8.8 to -7.2) at 12 months. QoL measurements also improved by 
between 2.2 (95% CI, -2.5 to -2.0) and  2.4 points (95% CI, -2.6 to -2.2) (MG). The sexual 
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health scores also indicated a small improvement, SMG ranged from 0.3 (95% CI, 0.2-0.4) 
and 0.4 (95% CI, 0.3-0.5) . 
Functional outcomes (Qmax and PVR) were inconsistently reported in the included studies, 
but Qmax showed a small improvement of between 3.8 ml/s (95% CI, 3.0-4.6) and 4.0 ml/s 
(95% CI, 3.4-4.6). The authors state that PVR results are significantly variable due to 
inconsitent reporting with very high heterogeneity estimates. 
 
Summary critique of clinical evidence submitted by the sponsor  
The sponsor presented a peer-reviewed systematic review (Perera et al., 2014) rather than 
their own literature search, data synthesis and analysis. However the systematic review 
included all of  the studies identified as relevant by the EAC in an independent literature 
search.  
Quality assessment of the systematic review (Perera et al., 2014) was performed by the EAC. 
Although some aspects of the review were reasonable there was insufficient methodological 
detail to fully explain their meta-analysis. Furthermore the quality of some of the included 
studies had a high risk of bias, 8/9 studies were uncontrolled before and after studies. 
Patient numbers in the analysis are not clearly explained. Perera et al., (2014) claimed that 
the pooled estimates were obtained from 888 to 1298 responses (depending on the score) 
from 452 to 680 patients. However, even if all the patients in all 10 studies listed in Table 2 
are summed, this would only give 650 patients, and some of these are common to more 
than one study e.g. Chin et al. (2012) and Woo et al. ( 2012), and the two LIFT Study papers 
(McVary et al., 2014 & Roehrborn et al., 2013). Also the authors state that some studies were 
not included in the final meta-analyses, but do not clearly state which studies these are.  
The results table presented gave pooled estimates of outcome measures with effect sizes, 
rather than using the units of individual outcome measures, which the EAC feel would be 
more transparent.  The authors present a difference in IPSS of -7.2 and -8.7 points (a 
negative IPSS score is a symptom improvement). This change in IPSS is a derived number, 
back-calculated to IPSS scores from the effect size in the meta-analysis, which in itself is 
calculated from pooled IPSS and BPHII numbers. As a result, this reports a worse IPSS 
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improvement than in all the publications included in the meta-analysis (the EAC-calculated 
weighted mean IPSS score is actually around -11 points). 
The potential for double-counting patients in these studies a lack of methodlogical clarity, 
and the somewhat short-form nature of a journal publication, means a lack of transparency 
in the authors’ methodology for the analyses.   
Summary of economic evidence submitted by the sponsor 
There were no published economic studies available on the Urolift device. The sponsor’s 
submission consisted of a very detailed de novo economic analysis and the sponsor 
submission was from the national NHS perspective. Data inputs for Urolift were collated 
from the LIFT study and expert clinical opinion. Outcome and complications costs were 
taken from a robust HTA (Laurenco et al. 2008).Comparators presented included TURP and 
HoLEP, as specified in the scope. The executable model included out-of scope-comparators 
such as laser resection and TUVP, which are not relevant for this assessment, but these 
were not included in the written submission. The time horizon was 2 years, which is 
appropriate, given the evidence base for Urolift.  
Summary critique of economic evidence submitted by the sponsor  
The sponsor’s model is very thorough, and the EAC note that it actually contains too much 
detail e.g. out of scope comparators (laser and TUVP). The model includes before and after 
procedure appointments that appear to be the same for all interventions (therefore making 
no difference to the cost outcomesThe base case submitted actually makes Urolift slightly 
cost incurring (by £3 per case) versus TURP and £418 per case versus HoLEP.  The sponsor’s 
breakdown of costs for each technology showed that the equipment costs per procedure for 
Urolift were much greater than for the comparators. Urolift had lower clinical supplies and 
services costs due to the estimated shorter length of hospital stay. Sensitivity analysis was 
somewhat limited and a range of ±20% was insufficient for some inputs, such as LOS for 
Urolift, where there was considerable uncertainty. 
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External Assessment Centre commentary on the robustness of evidence 
submitted by the sponsor  
The model is backed by robust data, comprising of Urolift data from the LIFT study and 
clinical opinion. Comparator data was taken from a thorough HTA authored by Laurenco et 
al. (2008). The EAC agreed with most of the inputs and assumptions used by the sponsor in 
the model. 
Summary of any additional work carried out by the External Assessment 
Centre 
For the clinical part of this assessment, the EAC designed and performed an independent 
literature search, and obtained a professional  translation of the Spanish-language 
manuscript for Abad et al. 2013. 
The EAC took a more simplified approach to the data presented in the studies for greater 
clarity. Firstly, we combined the three LIFT publications into a single set of results for the 
LIFT Study, and the two papers by Chin et al (2012) and Woo et al. (2012) to report from this 
64-patient cohort. We present data as changes from baseline, with means and weighted 
means to account for cohort sizes, in order to retain the data in the original units. We 
provide context for the results by citing clinically important changes in each measure from 
published sources, where available, and also by surveying clinical experts.  In order to 
provide some comparative context, we present changes from baseline in TURP and HoLEP 
from papers selected by a recent, methodologically robust  systematic review (Li et al. 
2014).  It should be noted that this is not true comparative data, but gives an idea of 
improvements from baseline and complications post-TURP and HoLEP, presented in the 
same format as the Urolift data. 
For the economic submission, the EAC checked the model inputs and corrected /adjusted 
them where necessary using a combination of published evidence and expert clinical 
opinion.  We performed sensitivity and threshold analysis in order identify the key drivers of 
the model as the cost of the Urolift device, operating time and length of stay. The EAC 
present a scenario in which Urolift can be cost-saving compared to mTURP and BiTURP, but 
not HoLEP. This relies upon a low number of Urolift implants, a short procedure time of 30 
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minutes or less, adding urological operating theatre overhead costs, local anaesthetic, and a 
day-case procedure of 0.125 days (3 hours). Under these conditions, savings of £336 
compared with mTURP and £209 compared with BiTURP are achievable.  All of the inputs of 
the EAC scenario are supported by published sources or by clinical experts for the 
assessment, who are currently using the Urolift device in the UK. 
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Table 1 Glossary 
Term Definition 
5-ARI 5-Alpha-Reductase Inhibitors 
AUASI American Urological Association Symptom Index (also known 
as IPSS score) 
AUR Acute Urinary Retention 
AUS Artificial Urinary Sphincter 
BiTURP Bipolar transurethral resection of prostate 
BPH Benign Prostatic Hyperplasia 
BSC Best Supportive Care 
HOLEP Holmium laser enucleation of the prostate 
IPSS International Prostate Symptom Score 
LCI Lower confidence interval 
LOS Length of stay 
LUTS Lower Urinary Tract Symptoms 
MG Mean Gain 
mTURP Monopolar transurethral resection of prostate 
NHS National Health System 
NICE National Institute for health and Clinical Excellence 
PSA Prostate Specific Antigen 
PSS Personal Social Services 
PUL Prostatic Urethral Lift 
QALY Quality Adjusted Life Year 
RCT Randomised Control Trial  
SHIM Sexual Health Inventory for Men (same as IIEF-5) 
SMG Standardised mean gain 
TUR Transurethral resection 
TURP Transurethral resection of the Prostate 
TUVP Transurethral Vaporisation of the Prostate 
UCI Upper confidence interval 
UK United Kingdom 
UTI Urinary tract infection 
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2 Background  
2.1 Overview and critique of sponsor’s description of clinical context 
The sponsor’s submission outlines the clinical context well, with references from published 
journals to support the statements made. They describe Lower Urinary Tract Symptoms 
(LUTS) and the resulting decrease in quality of life that accompanies the condition. They also 
correctly identify that medication is the first type of therapy used to treat the condition, and 
that this comes  with a number of unpleasant side-effects, noting that “over one quarter of 
patients discontinue medical therapy, often after only three months”. 
The sponsor refers to NICE IPG475, which has given “Normal Arrangements” for the use of 
prostatic urethral lift implants. It is worth noting that all the evidence in IPG475 is published 
data on the Urolift device, and there do not seem to be any competing devices for prostatic 
urethral lift. 
 The sponsor’s submission states, “no UK clinical pathways relevant to Urolift have been 
published to date”. However, the following overview is available on the NICE website, 
accompanying IPG475: 
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Figure 1 NICE clinical pathway for BPH 
 
Urolift would be placed in section 9 of this pathway, as an option for “Surgery for voiding 
symptoms”. In their submission, the sponsor specifically places Urolift in the pathway after 
the failure of drug management and prior to invasive surgical remedies (e.g. TURP, PVP, 
etc), which shows that they are aware of NICE clinical pathways and the EAC agrees that this 
placement of Urolift in the pathway is appropriate, as it is a minimally invasive procedure.  
2.2 Overview of sponsor’s description of ongoing studies 
The EAC conducted an independent search of Clinicaltrials.gov and WHO International 
Clinical Trials Registry Platform (ICTRP), and found the same ongoing clinical trials as noted 
by the Sponsor in their submission. Therefore, the EAC is in agreement with the sponsor’s 
submission.  The studies found were: 
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1) NCT01876706. Urolift System Tolerability  and ReCovery When Administering Local 
Anesthesia (active, not recruiting) 
2) NCT01533038. BPH-6: Comparison of the Urolift System to TURP for Benign Prostatic 
Hyperplasia (active, not recruiting) 
3) NCT01294150 . The Safety and Effectiveness of Urolift: LIFT Pivotal Study (active, not 
recruiting). 
The EAC is particularly interested in the results, or any preliminary analyses, arising from the 
BPH-6 trial, as it directly compares Urolift with TURP. As such, it is the only study that fully 
meets the scope for this assessment. However, the Clinicaltrials.gov listing denotes an end 
point of December 2015 for the BPH-6 trial and trial results are not available for inclusion in 
this report. 
2.3 Critique of sponsor’s definition of the decision problem 
Note: The Sponsor’s submission consists of a peer-reviewed systematic review by a separate 
group, Perera et al. (2014), rather than a de novo literature search followed by data 
extraction and synthesis/meta-analysis. Where possible, we will critique the Sponsor’s work, 
and also the systematic review by Perera et al. 2014. 
2.1.1 Population 
The sponsor’s submission contains studies that match the requirements of the NICE scope 
quite well. However, in table A1, the sponsor has misunderstood the table’s requirements. 
The aim of the table is to re-state what was asked by NICE in their scope, and then give an 
overview of the sponsor’s presented data with a rationale for any differences presented. 
The sponsor used the table to outline the state of BPH more generally in the UK – describing 
the total patient population, the number of surgical treatments per year, and the expected 
outcome measurements. One point the EAC would be interested in was the rationale behind 
the sponsor’s identification of TURP alone as the comparator to Urolift, rather than also 
including HoLEP, as in the NICE scope. The EAC completed the table, using the studies in the 
presented Perera et al. systematic review: 
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Table 2 EAC-completed Table A1 from sponsor submission template 
 Scope issued by NICE Variation from scope Rationale for variation 
Population Men with lower urinary 
tract symptoms (LUTS) 
secondary to benign 
prostatic hyperplasia 
(BPH) aged 50 or over, 
and with prostate 
volumes no greater than 
100 cc (100 g).  
None  
Intervention The UroLift system  None  
Comparator(s) Current practice varies 
and is changing as a 
result of which there are 
2 comparators:  
Monopolar or bipolar 
transurethral resection of 
the prostate (TURP)  
Holmium laser 
enucleation of the 
prostate (HoLEP)  
No comparative studies 
available – only one RCT 
vs sham control and 
uncontrolled before and 
after studies 
No comparative studies 
available. 
Outcomes The outcome measures 
to consider include:  
-Length of hospital stay  
-The need for, or 
duration of, 
catheterisation  
-Number of post 
discharge follow-on 
consultations, both in 
primary and secondary 
care settings  
-Time to re-operation 
and re-operation rates  
-Symptoms of BPH (using 
the International 
Prostate Symptom Score 
[IPSS])  
-Reduction in ejaculatory 
or sexual function  
-Time to return to normal 
Only “Healthcare-
associated infection” is 
not reported. UTIs, a 
device-related 
complication, are 
reported in the studies. 
Data not available – not a 
standard outcome for 
urological studies. 
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activities  
-Quality of life  
-Healthcare associated 
infection  
-Device-related adverse 
events 
 
Cost analysis Comparator(s): 
Monopolar or bipolar 
TURP and HoLEP  
Costs will be considered 
from an NHS and 
personal social services 
perspective.  
The time horizon for the 
cost analysis will be 
sufficiently long to reflect 
any differences in costs 
and consequences 
between the 
technologies being 
compared.  
Sensitivity analysis will be 
undertaken to address 
uncertainties in the 
model parameters, which 
will include scenarios in 
which different numbers 
and combinations of 
devices are needed.  
Sponsor’s cost model 
also submitted 
comparator costs for 
laser (e.g. Greenlight) 
transurethral 
vaporisation of the 
prostate (TUVP), and bi-
TUVP. 
 
Subgroups to be 
considered 
Men for whom TURP or 
HoLEP is unsuitable 
because of difficulties 
with blood loss or 
sedation.  
None  
Special considerations, 
including issues related 
to equality 
Men who wish to 
preserve sexual function 
and fertility.  
None – sexual function 
scores widely reported 
 
2.1.2 Intervention 
The sponsor’s submission matches the final scope issued by NICE. The submission was 
restricted to Urolift, the version of the device that has received CE marking and is sold in the 
UK.  
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The procedure is undertaken transurethrally with the patient under local or general 
anaesthesia. A pre-loaded delivery device is passed through a rigid sheath under cystoscopic 
visualisation. The delivery device is used to compress one lateral lobe of the prostate in an 
anterolateral direction towards the prostatic capsule. A needle is then advanced through 
the lobe and capsule, and a monofilament implant with two end pieces is deployed. One 
end of the implant is anchored in the urethra and the other on the outer surface of the 
prostatic capsule, retracting the prostatic lobe away from the urethral lumen. Multiple 
implants are usually inserted during each procedure (NICE IPG475). 
2.1.3 Comparator(s) 
The evidence submitted by the sponsor did not include any of the comparators detailed in 
the final scope, the scope called for comparative evidence against TURP or HoLEP. However, 
all studies submitted by the sponsor were either uncontrolled before and after studies or a 
RCT with a sham control. However, the available evidence is limited and the EAC did not find 
any comparative studies with Urolift vs. TURP or HOLEP in an independent literature search. 
The sponsor does point out that the study populations are similar, but this is still no 
substitute for a true comparative (preferably blinded) study, as this can be subject to 
selection bias, or outcomes can be interpreted differently due to detection bias in the 
different populations. 
2.1.4 Outcomes  
Primary clinical outcomes reported in the Perera et al. (2014) systematic review were: 
 Prostate symptoms (IPSS – International Prostate Symptom Score, and BPHII – BPH 
impact Index) 
 Sexual health (IIEF – International Index of Erectile Function, MSHQ – Male Sexual 
Health Questionnaires for ejaculatory function for ejaculatory function and Bother) 
 Functional parameters (Qmax – maximum urinary flow rate, and PVR – post void 
residual volume) 
 Procedural data (local anaesthetic, operative time and number of Urolift implants 
used 
 Time to re-operation, reported as “progression to TURP at 12 months” 
 Postoperative catheterisation 
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 Early postoperative complications, dysuria, haematuria, pelvic pain, urinary tract 
infection, incontinence)  
 Device-related adverse events 
The final scope listed additional outcomes, which were not reported in any of the identified 
studies. These were: 
 Length of hospital stay 
 Number of post-discharge follow-on consultations 
 Time to return to normal activities 
2.1.5 Cost analysis 
The cost analysis presented in the sponsor’s submission was a very detailed de novo 
economic analysis that matched the analysis specified in the scope. Costs were presented 
from national NHS perspective. Comparators presented included TURP and HoLEP, as 
specified in the scope. The time horizon is 2 years, which is appropriate, given the evidence 
base for Urolift, and outcome and complications are costed from a thorough HTA (Laurenco 
et al. 2008). 
2.1.6 Subgroups 
The scope specifies subgroups as men for whom, TURP or HoLEP is unsuitable because of 
difficulties with blood loss or sedation. Blood loss is not directly reported in the 
manufacturer’s submission, but some of the identified studies report transfusion rates as a 
complication of the Urolift procedure. The EAC note that this technology may be of a benefit 
to groups for whom blood transfusions are not an option e.g. Jehovah’s Witnesses.  
Sedation data (local versus general anaesthetic) is also addressed by a number of the 
publications.  
2.1.7 Special considerations, including issues related to equality 
Special considerations in the scope were for men who wished to preserve sexual function 
and fertility. Several of the papers in the systematic review had contained outcomes 
pertaining to sexual function, which addresses this concern. 
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No equality issues were identified in the scope. Neither the sponsor nor the EAC have 
identified any further equalities issues. 
 
 
Page 21 of 111 
 
MT241 Urolift 
Urolift Assessment Report 
3 Clinical evidence 
Note: The Sponsor did not present a de novo literature search and review for their clinical 
submission of evidence. A systematic review by Perera et al. (2014) was presented instead.  
The systematic review (Perera et al. (2014) included 10 studies: two reports from an RCT 
and eight uncontrolled before and after studies. 
3.1 Critique of the sponsor’s search strategy 
As noted above the sponsor did not undertake their own literature search. Instead, the 
sponsor described the literature search methods that were used in a recent, peer-reviewed 
systematic review (Perera et al. 2014). The search strategy is provided in the supplementary 
data that accompanies the systematic review publication.  The EAC critically appraised the 
systematic review (Perera et al. 2013) using a checklist designed by the Support Unit for 
Research Evidence, Cardiff University. 
The scope of the systematic review (Perera et al., 2014) lacked detail with regard to the 
population and comparators. The search strategy of the review was appropriate and the 
sources searched provided reasonable coverage for the review itself.  However the review 
did not include a search for clinical trials, adverse events or seek to obtain unpublished data 
all of which are required for a submission of evidence.  The sponsor attempted to seek 
unpublished data though this did not include contacting the authors of the included studies. 
The EAC designed a search strategy and performed an independent search of the literature, 
details in 3.9. 
 
3.2 Critique of the sponsor’s study selection 
Inclusion and exclusion criteria were briefly described, and copied directly from the 
methods section of Perera et al. (2104). Studies reporting functional sexual outcomes 
following the urethral lift procedure for LUTS secondary to BPE were included. No language 
or sample-size restrictions were used. Conference proceedings were not included.  
For publications where duplicate study populations or repeated data were identified, the 
publications reporting the larger sample size was used. However, due to the lack of 
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transparency in the methods presented by the Sponsor (specifically in the meta-analysis), 
the EAC took a more simplified approach to the analysis of data presented in the studies. 
Certain publications (Chin et al., 2012 and Woo et al., 2012, and those reporting the LIFT 
Study) were collated together to avoid double-reporting of results from the same patient 
cohorts (see section 3.9 – Additional work carried out by the EAC). 
3.3 Included and excluded studies 
Of 61 suitable studies, 23 conference proceedings and 28 editorials were excluded by Perera 
et al. (2014). One published study (Abad et al. 2013) was also excluded, as it did not report 
standard deviations. Nine studies were finally included: 
Table 3 Included and excluded studies 
Study Country Study Description 
S quality assessment 
system ample size 
Abad et al. 
2013 
(excluded by 
Sponsor) 
Spain Uncontrolled before and after study 20 
Cantwell et 
al., 2013 
,USA, Canada and 
Australia.  
19 centre study 
Before and after study to assess Urolift in patients who 
had previously been randomised to the sham arm of the 
LIFT study. After the primary endpoint comparison at 3 
months, sham controls were unblinded and offered 
enrolment into this study. 
53 
(patients elected to 
have PUL after sham in 
the LIFT study) 
 
Chin et al. , 
2012 (same 
cohort as Woo 
et al. 2012 – 
see below) 
 
Australia  
6 centre study 
Multicentre uncontrolled before and after study. 
 
64 
 
Delongchamps 
et al., 2012 
France 
Single centre prospective uncontrolled before and after 
study. 
4 
Roehrborn et 
al., 2013 
(LIFT Study) 
19 centre study: 
USA 14 
Canada 2 
Australia 3 
RCT, 2:1 randomisation between Urolift and sham control. 
Sham control: patient blinded and given rigid cystoscopy, 
no implants used. 
Urolift group: 140 
Control group: 66 
McVary et al., 
2014 
(LIFT Study) 
19 centre study: 
USA 14 
Canada 2 
Australia 3 
RCT, 2:1 randomisation between Urolift and sham control. 
Sham control: patient blinded and given rigid cystoscopy, 
no implants used. 
Urolift group: 140 
Control group: 66 
 
McNicholas et 
al., 2013 
7 centres in 5 
countries. 
Not clearly 
stated, authors 
are from UK, 
Australia, USA, 
Spain, Germany, 
Retrospective analysis of prospectively accrued data from 
consecutive multicentre uncontrolled before and after 
study. 
102 
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The Netherlands 
and Italy. 
Shore et al., 
2014 
Not reported Uncontrolled before and after study. 51 
Woo et al., 
2011 
Australia 
Prospective, non-randomised uncontrolled before and 
after study, assessing safety and feasibility. 
19 
Woo et al., 
2012 (same 
cohort as Chin 
et al. 2012 – 
see above) 
Australia  
6 centre study 
Multicentre uncontrolled before and after study. 
 
64 
 
The EAC’s independent literature search did not find any additional studies over those found 
by the sponsor. Alongside the systematic review by Perera et al. (2014), the sponsor also 
provided one additional publication: a 2-year update on the LIFT Study by Roehrborn et al. 
2014. The sponsor states “the results do not materially change the meta-analysis and thus 
Perera et al. (2014) stands as relevant and current”. 
Delongchamps et al. (2012), a study published in French with only 4 patients, was excluded 
as it was not considered to be a pivotal study for this assessment. 
 Summary of the key points in each study: 
Abad et al. (2013) (Not included in Sponsor’s meta-analysis): 
Patient 
population  
Sample 
size 
 Country Mean 
age±SD 
Mean 
baseline 
IPSS, or 
BHPII ±SD 
Mean 
baseline IIEF 
or MSHQ 
±SD 
Mean 
baseline 
Qmax ±SD 
Mean 
baseline 
prostate 
volume ±SD 
Mean baseline 
PVR ±SD 
Study design 
Inclusion criteria: 
Age ≥50, IPSS >20, 
Qmax <15ml/s, 
PSA<10 ng/ml 
Exclusion criteria: 
Obstructing 
medial lobe 
(observed with 
cystoscopy), 
urinary tract 
infection, 
previous surgical 
treatment for 
prostate 
pathology.  
Urolift 
group: 
20  
Withdra
wals: 
None 
Note: 
No SDs 
reporte
d for 
baseline
s or 
results. 
 Spain Mean 
74.3 
(range 
43-90) 
years 
 
IPSS 26.7, 
(range 20-
35) 
 
Not reported All patients: 
Mean 6.9 
(range 0-13 
ml/s 
Excluding 4 
patients 
catheterised 
at baseline 
due to 
chronic 
retention: 
Mean 
8.6ml/s 
(range 3-13) 
 42.6 (range 
19-109) cc 
(TRUS) 
 
Not reported Retrospective uncontrolled before 
and after study. 
Primary endpoints: evaluate the 
effectiveness  of Urolift and the 
number and intensity of side effects 
post-procedure 
Follow-up: 
 IPSS, BPHII and Qmax at 4 weeks, 3, 
6 and 12 months.  
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Cantwell et al. (2013): 
Patient population  Sample size Country Mean 
age±SD 
Mean 
baseline 
IPSS, or 
BHPII ±SD 
Mean 
baseline IIEF 
or MSHQ ±SD 
Mean 
baseline 
Qmax ±SD 
Mean 
baseline 
prostate 
volume ±SD 
Mean baseline 
PVR ±SD 
Study design 
Inclusion criteria: 
≥50 years old, 
provided informed 
consent, no prior 
surgical BPH 
treatment, washed 
out or naive to α-
blockers or 5 α-
reductase inhibitors. 
IPSS ≥13, Qmax 
≤12ml/s with a 
voided volume of 
125ml. Prostate 
volume of 30-80ml, 
without an 
obstructing median 
lobe. 
Exclusion criteria: 
Retention, post-void 
residual volume 
(PVR) >250ml, active 
infection, PSA 
>10ng/ml unless 
negative biopsy, 
cystolithiasis within 3 
months, bacterial 
prostatitis within 1 
year.  
53 patients 
elected to have 
PUL after sham in 
the LIFT study. 
Withdrawals: 
None 
19 
centre 
study, 
USA, 
Canada 
and 
Australi
a. 
64±8.0, 
range 
50-79) 
years 
 
IPSS 
23.3±5.5, 
(range 13-
34) 
IPSS QoL 
4.5±1.2 
(range 2-6) 
BPHII (n=52) 
6.3±3.0 
(range 1-12) 
IIEF (n=53) 
12.8±8.3, 
(range 1-25) 
MSHQ-EjD 
(n=42) 
9.5±10.0 
(range 3-14) 
.8±4.2 
(range 2.0-
30.0) ml/s 
 
 40.3±9.9 
(range 30-
68) mls 
 
67.8±66.44 
(range 0-262) 
mls 
 
Before and after study to assess 
Urolift in patients who had previously 
been randomised to the sham arm of 
the LIFT study. 
Primary endpoints were symptom 
scores, QoL and sexual health 
questionnaire scores. 
Follow-up: 
 IPSS, IPSS QoL BPHII, IIEF-5 and 
MSHQ were 2 weeks, 1, 3, 6 and 12  
months. Qmax and PVR at 3 and 12 
months. Safety was assessed at each 
follow-up visit  
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Chin et al. (2013)  
Patient population  Sample size Country Mean 
age±SD  
Mean baseline 
IPSS, or BHPII 
±SD 
Mean baseline 
IIEF or MSHQ 
±SD 
Mean baseline 
Qmax ±SD 
Mean baseline 
prostate volume 
±SD 
Mean baseline 
PVR ±SD 
Study design 
Inclusion criteria: 
≥55 years of age,. 
Symptomatic BPH, 
IPSS>13, PVR<250ml, 
peak Qmax of 5-
12ml/s. Wash-out of 
α-blockers for 1 
week and 5 α-
reductase inhibitors  
within 6 months of 
treatment. 
Exclusion criteria: 
PSA >10ng/ml, 
history of urinary 
retention, previous 
prostate surgery, 
compromised renal 
function, current 
infection, 
obstructive median 
lobes. 
Urolift 
group: 
64 
Withdrawals: 
Not reported 
Australia 
(6 
different 
centres) 
66.9 ±7.3 
years (range 
53-83) 
 
IPSS:  Not 
reported for 
total cohort, but 
varies 
throughout 
follow-up 
 
Duration of LUTS 
= 4.7±4.3 years 
(range 0.5-23) 
Not reported for 
total cohort, but 
varies 
throughout 
follow-up 
Not reported for 
total cohort, but 
varies 
throughout 
follow-up 
51 ±23 mls 
(range 21-149) 
(TRUS) 
Not reported for 
total cohort, but 
varies 
throughout 
follow-up 
Multicentre 
uncontrolled before 
and after study. 
 Primary endpoints 
were longer-term 
effectiveness of PUL 
in relieving LUTS  
Follow-up: 
 2 weeks, and 3,6,12 
and 24 months 
IPSS results were 
analysed on a) the 
entire dataset and b) 
patients 26-64 only. 
Patients 26-64 had 
the most recent 
version of Urolift 
device (3 
generations of 
device used over the 
total cohort) and 
refined method 
used, where implant 
placement formed 
continuous channel 
from bladder neck to 
verumontanum.  
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Roerhborn et al. 2013 (the LIFT Study): 
Patient population  Sample size Country Mean 
age±SD  
Mean baseline 
IPSS, or BHPII 
±SD 
Mean baseline 
IIEF or MSHQ 
±SD 
Mean baseline 
Qmax ±SD 
Mean baseline 
prostate 
volume ±SD 
Mean baseline 
PVR ±SD 
Study design 
Inclusion criteria  
≥50 years of age, 
provided consent, , 
no prior BPH 
surgical treatment, 
washout of 2 
weeks for α-
blockers, 3 months 
for 5-α-reductase 
inhibitors, 3 days 
for anticoagulants, 
IPSS>13, Qmax 
≤12ml/s, 125ml 
voided volume, 30-
80cc prostate 
volume (via TRUS). 
Exclusion criteria: 
Median lobe 
obstruction, 
retention, PVR 
>250ml, active 
infection, PSA 
>10ng/ml (unless 
negative biopsy), 
cystolithiasis within 
3 months and 
bacterial prostatitis 
within 1 year. 
Urolift group: 
140 
Ctrl group: 
66 
Withdrawals: 
7 censored due to 
use of BPH 
medication 
1 subject 
discontinued 
participation 
2 exclusions due to 
significant protocol 
violations 
19 centres: 
USA 14 
Canada 2 
Australia 3 
Urolift 
group: 
67±8.6 
years 
Ctrl group: 
65±8.0 
years 
 
Urolift group: 
IPSS 22.2±5.4 
Ctrl group: 
Mean 24.4±5.8  
 
Urolift group: 
IPSS  QoL 
4.6±1.1 
Ctrl group: 
IPSS QoL 
4.7±1.1 
 
 
BPHII baselines 
not reported 
Urolift group: 
IIEF 13.0±8.4  
MSHQ-EjD 
8.7±3.2 
Ctrl group: 
IIEF 13.5±8.5  
MSHQ-EjD 
8.8±3.2 
 
Urolift group: 
8.9±2.2 ml/s 
Ctrl group: 
8.8±2.2 ml/s 
 
Urolift group: 
44.5±12.4 mls 
Ctrl group: 
40.9± 10.8 mls 
 
Urolift group: 
85.5±69.2 mls 
Ctrl group: 
87.7± 72.4 mls 
 
RCT, 2:1 
randomisation 
between Urolift and 
sham control. 
Sham control: 
patient blinded and 
given rigid 
cystoscopy, no 
implants used. 
Primary endpoint: 
reduction in IPSS at 3 
months after PUL 
procedure was at 
least 25% better 
than sham. 
Follow-up: 
 IPSS, QoL, BPHII, IIEF 
and MSHQ-EjD 
assessed at 2 weeks, 
1,3, 6,12 and 24 
months. 
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McNicholas et al. 2013 
Patient population  Sample size Country Mean 
age±SD 
Mean baseline 
IPSS, or BHPII 
±SD 
Mean baseline 
IIEF or MSHQ 
±SD 
Mean 
baseline 
Qmax ±SD 
Mean baseline 
prostate 
volume ±SD 
Mean baseline PVR 
±SD 
Study design 
Inclusion criteria: 
Prostate volume 
<60mls, IPSS>12, 
Qmax<15ml/s, 
PVR<350 
NOTE: these are 
“typical inclusions” 
 
No exclusion criteria 
reported 
102  7 centres in 5 
countries.  
Not clearly 
stated, authors 
are from UK, 
Australia, USA, 
Spain, 
Germany, The 
Netherlands 
and Italy. 
Mean 
68±10 
years 
 
IPSS 23.2±6.1 
IPSS QoL 
4.7±1.0  
 
Not reported 
for total cohort, 
but varies 
throughout 
follow-up  
8.7±4.0 ml/s 48±21mls 
 
Not reported for 
total cohort, but 
varies throughout 
follow-up 
Retrospective 
analysis of 
prospectively 
accrued data from 
consecutive 
uncontrolled before 
and after study.  
Primary endpoints 
were to evaluate 
safety and efficacy 
with the most 
current Urolift 
device and surgical 
technique in day-to-
day practice.  
Follow-up: 
 2 and 6 weeks, 3,6 
and 12 months 
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McVary et al. 2014 (the LIFT Study): 
Patient population  Sample size Country Mean age 
±SD 
Mean 
baseline IPSS, 
or BHPII ±SD 
Mean baseline 
IIEF or MSHQ 
±SD 
Mean 
baseline 
Qmax ±SD 
Mean 
baseline 
prostate 
volume ±SD 
Mean 
baseline 
PVR ±SD 
Study design 
Inclusion criteria  
>50 years of age, provided 
consent, , no prior BPH 
surgical treatment, 
washout of 2 weeks for α-
blockers, 3 months for 5-α-
reductase inhibitors, 3 days 
for anticoagulants, IPSS 
≥13, Qmax ≤12ml/s, 125ml 
voided volume, 30-80cc 
prostate volume (via 
TRUS). 
Exclusion criteria: 
Median lobe obstruction, 
retention, PVR >250ml, 
active infection, PSA 
>10ng/ml (unless negative 
biopsy), cystolithiasis 
within 3 months and 
bacterial prostatitis within 
1 year. 
Urolift group: 
140 
Ctrl group: 
66 
 
Withdrawals: 
7 censored 
due to use of 
BPH 
medication 
1 subject 
discontinued 
participation 
2 exclusions 
due to 
significant 
protocol 
violations 
19 centres: 
USA 14 
Canada 2 
Australia 3 
Urolift 
group: 
67 years 
Ctrl group: 
65 years 
 
Note: SDs 
not 
reported by 
McVary but 
cohort is 
the same as 
Roerhborn 
et al. 2013 
above. 
 
Urolift group: 
IPSS 22  
Ctrl group: 
IPSS 24  
 
Urolift group: 
IPSS  QoL 4.6 
Ctrl group: 
IPSS QoL 4.7  
 
Urolift group: 
IIEF 13.0  
Ctrl group: 
IIEF 13.5  
 
Urolift group: 
8.9 ml/s 
Ctrl group: 
8.8 ml/s 
 
Not reported 
 
Not 
reported 
 
RCT, 2:1 randomisation 
between Urolift and 
sham control. 
Shame control: patient 
blinded and given rigid 
cystoscopy, no implants 
used. 
Primary endpoint: 
Change in IPSS and sexual 
health measures (IIEF and 
MSHQ) up to 12 months 
post-PUL 
Follow-up: 
 QoL, BPHII, IIEF and 
MSHQ-EjD assessed at 2 
weeks, 1,3,6,12 and 24 
months. 
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Shore et al. 2014: 
Patient population  Sample size Country Mean age±SD Mean baseline IPSS, 
or BHPII ±SD 
Mean baseline IIEF 
or MSHQ ±SD 
Mean 
baseline 
Qmax ±SD 
Mean baseline 
prostate volume 
±SD 
Mean 
baseline 
PVR ±SD 
Study design 
Inclusion criteria: 
≥50 years of age, 
provided informed 
written consent, had no 
prior surgical BPH 
treatment, wased out 
or naive to α-blockers 
and 5- α-reductase 
inhibitors. IPSS ≥13. 
Qmax <12ml/s, prostate 
volume 30-80cc without 
obstructing median 
lobe. 
Exclusion criteria: 
Current urinary 
retention, PVR >250ml, 
active infection, gross 
haematuria, 
cystolithiasis, within 3 
months, bacterial 
prostatitis within 1 year. 
51 NR 66±7.6 years 
(range 51-85) 
IPSS 21.45±5.43  
(range 13-32) 
BPHII 6.65±3.08 
IIEF 16.51±7.33 
ml/s  (range 2-25) 
 
MSHQ-EjD 
9.95±2.59 (range 5-
15) 
8.22±2.18  
 (range 2-
12.0) 
41.3±11.6 cc 
(range 30.0-77.3) 
77.05±74.92 
mls (range 
0-247) 
 
Non-blinded 
uncontrolled 
before and after 
study. 
Primary 
endpoint: 
ascertain 
whether 80% of 
patients achieve 
a score of ≥80 
on the Quality 
of Recovery 
Visual Analogue 
Scale (QoR VAS) 
by 1 month 
follow-up. 
Follow-up: 
2 weeks, and 1 
month 
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Woo et al. 2011: 
Patient population  Sample size Country Age±SD Mean baseline IPSS, 
or BHPII ±SD 
Mean baseline IIEF 
or MSHQ ±SD 
Mean 
baseline 
Qmax ±SD 
Mean baseline 
prostate volume 
±SD 
Mean 
baseline 
PVR ±SD 
Study design 
Inclusion criteria: 
IPSS ≥13, Qmax 5-
12ml/s, prostate 
volume 20-100ml, PVR 
<250ml, PSA <10ng/ml.  
Exclusion criteria: 
Median lobe 
obstruction, current 
infection, history of 
urinary retention, α-
adrenergic receptor 
blocking medication 
within 1 week, or 5-α-
reductase inhibitor 
medication within 6 
months of treatment, 
history of significant 
medical co-morbidity,  
prior BPH surgery, or if 
had a known or 
suspected urological 
condition that may 
affect voiding function. 
19 Australia Mean 66±6 
years 
(range 55-
77) 
Not reported for 
total cohort, but 
varies throughout 
follow-up  
Not reported  Not 
reported for 
total cohort, 
but varies 
throughout 
follow-up  
 
Mean 49±20 mls 
(range 21-97) 
 
Not 
reported 
for total 
cohort, but 
varies 
throughout 
follow-up  
 
Prospective, non-
randomised 
safety and 
feasibility study 
Primary aim: 
Safety: Evaluate 
number and 
severity of SAEs 
up to 12 months 
follow-up 
Feasibility: 
deliver sutures to 
increase urethral 
lumen 
Follow-up: 
 IPSS and QoL at 
2 weeks, 3, 6 and 
12 months 
 
 
 
Woo et al. 2012: 
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Patient population  Sample size Country Age±SD Mean baseline IPSS, 
or BHPII ±SD 
Mean baseline IIEF 
or MSHQ ±SD 
Mean 
baseline 
Qmax ±SD 
Mean baseline 
prostate volume 
±SD 
Mean 
baseline 
PVR ±SD 
Study design 
Inclusion criteria: 
≥55 years of age,. 
Symptomatic BPH, 
IPSS>13, PVR<250ml, 
peak Qmax of 5-12ml/s. 
Wash-out of α-blockers 
for 1 week and 5 α-
reductase inhibitors  
within 6 months of 
treatment. 
Exclusion criteria: 
PSA >10ng/ml, history of 
urinary retention, 
previous prostate 
surgery, compromised 
renal function, current 
infection, obstructive 
median lobes. 
Urolift group: 
64 
Withdrawals: 
Not reported 
Australia 
(6 
different 
centres) 
66.9 ±7.3 
years (range 
53-83) 
 
IPSS: 22.9 ±5.4 
(range 14-35, n=64) 
Duration of LUTS = 
4.7±4.3 years 
IIEF: 11.7(±8.6) 
(range 1-25, n=58) 
MSHQ-EjD: 9.0±3.7 
(range 1-15, n=46) 
MSHQ-Bother: 1.7 
±1.5 (range 0-5 , 
n=46) 
Not 
reported 
 
51 ±23 mls (range 
21-149) 
(TRUS) 
Not 
reported 
Multicentre 
uncontrolled before 
and after study. 
Primary endpoint: 
effect of PUL on 
erectile and 
ejaculatory 
function  
Follow-up: 
 2 weeks, and 3,6, 
and 12 months 
 
 
 
 3.4 Overview of methodologies of all included studies 
 
Table 4 Overview of methodologies of all studies 
Study Methods 
Abad et al. 
2013  
(not included in 
Sponsor’s 
submission) 
Primary endpoints:  Evaluate the effectiveness  of Urolift and the number and intensity of 
side effects post-procedure 
Follow-up:  IPSS, BPHII and Qmax at 4 weeks, 3, 6 and 12  months.  
Statistical methods: Changes from baseline measurements compared and Wilcoxon 
nonparametric test used. Significance calculated as p<0.05. 
Cantwell et al. 
2013 
Primary endpoints: Symptom scores, QoL and sexual health questionnaire scores. 
Follow-up:  IPSS, IPSS QoL and BPHII were assessed at 2 weeks, 1 and 3 months after both 
the sham and PUL and additionally at 6 and 12 months post-PUL. IIEF-5, MSHQ-EjD and 
MSHQ-Bother were also assessed at the same time-points in sexually active patients. Qmax 
and PVR assessed at 3 and 12 months. Safety was assessed at each follow-up visit through 
adverse event reporting. 
Statistical methods: Descriptive statistics used for IPSS, IPSS QoL, BPHII, Qmax, PVR, IIEF-5, 
MSHQ-EjD. Students t-test used to compare changes from baseline to 3 months between 
sham and PUL. 
Chin et al. 2012 
Primary endpoints: longer-term effectiveness of PUL in relieving LUTS  
Follow-up:  2 weeks, and 3,6,12 and 24 months 
Statistical methods: To evaluate change from baseline, a general estimating equation 
model was fit to each outcome parameter (IPSS, QoL, BPHII, Qmax, PVR, IIEF (SHIM) and 
MSHQ-EjD). To address potential effects of the device and procedural changes made during 
the study, IPSS results were analysed on a) the entire dataset and b) patients 26-64 only. 
Roehrborn et 
al. 2013  
(The LIFT Study) 
 
Primary endpoint: Reduction in AUASI (IPSS, on an intention-to-treat basis) at 3 months 
after PUL procedure was at least 25% better than sham. 
Follow-up:  QoL, BPHII, IIEF and MSHQ-EjD assessed at 2 weeks, 1,3,6,12 months. 
Statistical methods: The study was powered for the primary endpoint assuming a Student’s 
t test comparison of mean values on an ITT basis, 0.05 2-sided type-1 error and 80% power. 
For per-protocol analysis to evaluate change from baseline, a general estimating equation 
model was fit to each outcome parameter. 
McVary et al. 
2013 
(The LIFT Study) 
Primary endpoint: Change in IPSS and sexual health measures (IIEF and MSHQ) up to 12 
months post-PUL 
Follow-up:  QoL, BPHII, IIEF and MSHQ-EjD assessed at 2 weeks, 1,3,6, and 12 months. 
Statistical methods: The study was powered for the primary endpoint assuming a Student’s 
t test comparison of mean values on an ITT basis, 0.05 2-sided type-1 error and 80% power. 
For per-protocol analysis to evaluate change from baseline, a general estimating equation 
model was fit to each outcome parameter. 
McNicholas et 
al. 2013 
Primary endpoints: Evaluate safety and efficacy with the most current Urolift device and 
surgical technique in day-to-day practice.  
Follow-up:  2 and 6 weeks, 3,6 and 12 months 
Statistical methods: To evaluate change from baseline, a general estimating equation 
model was fit to each outcome parameter (IPSS, QoL, BPHII, Qmax, PVR, IIEF (SHIM) and 
MSHQ-EjD). 
Shore et al. 
2014 
Primary endpoint: Ascertain whether 80% of patients achieve a score of ≥80 on the Quality 
of Recovery Visual Analogue Scale (QoR VAS) by 1-month follow-up. 
Follow-up: 2 weeks, and 1 month 
Statistical methods: Primary endpoint tested by calculating the one-sided 95% confidence 
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limit using the Clopper-Pearson method. Descriptive statistics used for IPSS, IPSS QoL, BPHII, 
Qmax, PVR, IIEF-5, MSHQ-EjD. A general estimating equation model was fit to each outcome 
parameter. 
Woo et al. 2011 
Primary aims: Safety: Evaluate number and severity of SAEs up to 12 months follow-up 
Feasibility: deliver sutures to increase urethral lumen 
Follow-up:  IPSS and QoL at 2 weeks, 3, 6 and 12 months 
Statistical methods: Not reported. 
Woo et al. 2012 
Primary endpoints: Effect of PUL on erectile and ejaculatory function  
Follow-up:  2 weeks, and 3,6,and 12 months 
Statistical methods: To evaluate change from baseline, a general estimating equation 
model was fit to each outcome parameter (IPSS, QoL, BPHII, Qmax, PVR, IIEF (SHIM) and 
MSHQ-EjD). To address potential effects of the device and procedural changes made during 
the study, IPSS results were analysed on a) the entire dataset and b) patients 26-64 only. 
 
3.5 Overview and critique of the sponsor’s critical appraisal 
The sponsor’s submission contained a number of tables with critical appraisals for the 
studies within the Perera et. al. systematic review. The table template used was designated 
for randomised controlled trial (RCT) appraisal, and appropriately used for the two LIFT 
Study papers (Roerhborn et al. 2013 and McVary et al. 2014). All other studies are 
uncontrolled before and after studies and were appraised appropriately with a tool for 
observational studies. 
Quality assessment in the systematic review by Perera et al. (2014) is described very briefly. 
Studies were quality assessed by two researchers, working independently, using a method 
based on The Cochrane Handbook for Systematic Reviews of Interventions 5.02. 
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3.6 Results  
Table 5 Sponsor’s submission meta-analysis results, as presented in Perera et al. 2014 
 1 month 3 month 12 month 24 month 
Prostate symptom 
scores (IPSS, BPHII) 
No of data sources, 
response sample size 
(n) 
9 (1298) 6 (1050) 6(1022) 6 (888) 
Effect size (95% CI) -1.30 (-1.4 to -1.2) -1.50 (-1.7 to -1.4) -1.6 (-1.7 to -1.3) -1.5 (-1.6 to -1.3) 
Heterogeneity (τ
2
) 0.1 0.1 0.00 0.00 
Male sexual health 
scores (IIEF, MSHQ-
EjD, MSHQ-Bother) 
No of data sources, 
response sample size 
(n) 
13 (1042) 9 (889) 9 (908) 9 (786) 
Effect size (95% CI) 0.4 (0.3 to 0.5) 0.4 (0.3 to 0.5) 0.4 (0.3 to 0.5) 0.3 (0.2 to 0.4) 
Heterogeneity (τ
2
) 0.00 0.00 0.00 0.00 
Health related QoL 
No of data sources, 
response sample size 
(n) 
4 (628) 3 (508) 3 (496) 4 (452) 
Effect size (95% CI) -2.2 (-2.5 to -2.0) -2.4 (-2.6 to -2.2) -2.4 (-2.6 to -2.2) -2.2 (-2.4 to -2.1) 
Heterogeneity (τ
2
) 0.2 0.1 0.1 0.00 
Maximum flow rate 
(Qmax) 
No of data sources, 
response sample size 
(n) 
3 (242) 3 (488) 1 (106) 3 (362) 
Effect size (95% CI) 3.8 (3.0 to 4.6) 4.0 (3.4 to 4.6) 4.4 (3.2 to 5.6) 3.8 (3.1 to 4.4) 
Heterogeneity (τ
2
) 0.4 0.03 NA 0.2 
Postvoid residual 
(PVR) 
No of data sources, 
response sample size 
(n) 
2 (128) 2 (396) 
1 (122) 
Note: this is data 
from a single study 
2 (350) 
Effect size (95% CI) 15.5 (12.6 to 18.6) -6.2 (-10.1 to -2.8) -11 (-13 to -9) -4.0 (-10.5 to 2.6) 
Heterogeneity (τ
2
) 1732 24 NA 219 
 
The presentation of the meta-analysis makes it difficult to elucidate which studies are being 
used by the sponsor, as it is not explicitly stated. The number of studies using different 
outcome measures varies but exact studies are not identified by name.  
Raw data are not presented at all, and therefore this is difficult to discuss, as the results are 
presented in meta-analysis form only, with a separate table for collated complications (see 
Section 3.7 below). 
Each study does contain the relevant patient population (elucidated by the EAC after 
gathering the included papers), and uses Urolift as the intervention, which is within scope. 
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There were no comparators (the scope required comparative studies with TURP or HoLEP, 
as discussed previously) because identified studies were either case series or a single RCT 
against a sham control. No comparative studies for Urolift against TURP or HoLEP exist at 
the time of writing. 
The lack of detail in the results presentation in the sponsor’s submission means that it is 
more appropriate to critique the meta-analysis by Perera et al. – see Section 3.8. 
3.7 Description of the adverse events reported by the sponsor 
The operative details and complications are reported in one unified table that the sponsor 
presented from Perera et al. (2014). Complications are not combined, but reported for each 
publication separately. 
Operative details are: 
 Local anaesthetic (incidence of use), operative time (mins), implants (meaning 
number of Urolift implant sutures used in the procedure), postoperative catheter 
(patient numbers needing catheterisation, or catheterised as per hospital protocol). 
Complications reported are: 
 Early postoperative complications: 
o Dysuria, haematuria, pelvic pain, UTI (urinary tract infection), Incontinence 
 Progression to TURP at 12 months 
The EAC feels that the adverse events reported are quite mild, with the most common 
complications being short-term dysuria and haematuria.  
One item of greater concern is the variability in progression to TURP at 12 months – this is 
reported as being as low as 1.4% (LIFT Study, Roerhborn et al. 2013) but as high as 19% 
(Chin et al. 2012).  
The authors also mention implant encrustation and quantify it in the text of the review. This 
is reported in one of the studies (publications by Chin et al. 2012 and Woo et al 2012), and 
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occurs when implants are placed too close to the bladder, exposed to static urine. Two out 
of fourteen encrusted implants required removal with endoscopic forceps. This is important 
as a Urolift-specific complication that will not arise with TURP or HoLEP. In order to get 
more detail on this issue, the EAC consulted clinical experts on the severity of implant 
encrustation. The opinions varied due to there being very little long-term data available on 
Urolift. Three experts stated that encrustation is a significant issue, with one detailing that 
they will gradually become stones over time, potentially causing an infection. Two experts 
did not see encrustation as a significant issue, and one further expert stated that he did not 
know due to lack of long-term data. The majority of experts stated that the removal of 
encrusted implants was a simple procedure, but one expert was concerned that a TURP or 
HoLEP to remove encrusted implants was more complex than a standard procedure. 
The EAC were also concerned that the Urolift implants themselves may cause a problem if a 
patient progresses to TURP. This may be through conduction of heat or electricity from the 
electrosurgery loop. The EAC asked Specialist advisers about this issue, and were reassured 
that it is not a concern, particularly from Specialists who had performed a post-Urolift TURP 
in practice. One published source (Woo et al. 2011) mentions that three patients in their 
case series required TURP and the Urolift implants were cut without difficulty and no 
alteration of the TURP procedure was required. This was also the case in Chin et al. 2012, 
where patients were re-treated with TURP, photoselective vaporisation of the prostate or 
repeat Urolift procedure. Each retreatment method was performed routinely, unaffected by 
the presence of the Urolift implants. 
 Our EAC data analysis shows that not all complications are reported in the systematic 
review, so we will attempt to rectify this in Section 3.9. 
3.8 Description and critique of evidence synthesis and meta-analysis carried 
out by the sponsor 
The meta-analysis results presented by the sponsor are shown in Section 3.7 and are the 
only (non-complication) outcome measure results in Perera et al. (2014). 
The systematic review gives insufficient methodological detail to fully explain their meta-
analysis. The results table presented gives pooled estimates of outcome measures with 
 
 
Page 38 of 111 
 
MT241 Urolift 
Urolift Assessment Report 
effect sizes, rather than using the units of individual outcome measures, which the EAC feel 
would be more transparent. Below are categorised notes on the meta-analysis: 
Patient numbers 
The authors claimed that the pooled estimates were obtained from 888 to 1298 responses 
(depending on the score) from 452 to 680 patients. However, even if all the patients in all 10 
studies listed in Table 2 are summed, this would only give 650 patients, and some of these 
are common to more than one study e.g. Chin et al 2012 and Woo et al. 2012, and the two 
LIFT Study papers (and this despite the fact that the authors stated that some studies were 
not included in the final meta-analyses).  The EAC has attempted to contact the authors 
regarding this issue but received no response. 
Making an assumption of which five studies were included in the final meta-analyses gives a 
total number of 53 (Cantwell et al., 2014) + 140 [Lift Study (McVary et al., 2014 & Roehrborn 
et al.,  2013)] + 51 (Shore et al., 2014) + 102 (McNicholas et al., 2013) + 64 (Chin et al. 2012) 
= 410 patients, much less than the numbers quoted by the authors. 
Further, in Table 4, the number of studies included in the analysis in many of the cells 
exceeds either 5 or 6, with up to 13 studies being included for one analysis (with 1042 
responses). It is not clear which studies have been included in each of the analyses. 
Note that in the abstract, it is stated that 6 independent patient cohorts were included for 
analysis, although the conclusions state 5. 
Presentation of meta-analyses 
Presumably, the primary outcome of interest is the change in IPSS and whether there is a 
significant improvement; or, alternatively, whether the improvement is similar to that found 
when using other established methods, but with fewer side effects. 
However, the Perera et al. (2014) present the outcome as a compound ‘prostate symptom 
score’ (IPSS and BPHII combined) in Figure 2 and Table 4, so it is difficult (if not impossible) 
to determine how much the IPSS itself has changed following the procedure. 
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The authors present in the abstract that there was a difference in IPSS of -7.2 to -8.7 points, 
but with no indication if this is a range, a confidence interval or at which time-point(s). In 
the discussion, this is stated as an improvement of -8.0 points (95% CI, -8.8 to -7.2) at 12-mo 
follow-up. In fact, the change in IPSS is a derived number, calculated as follows (according to 
Data extraction and analysis): 
The standardised mean gain (SMG) was calculated from the pooled standard deviation of 
the multiple scales comprising the prostate symptom score. The SMG and its 95% CI were 
then multiplied by 5.5, which ‘represents a typical standard deviation for the IPSS scores’. 
Moreover, the authors state that ‘This interpretation should be considered indicative only’. 
This caution is not repeated in the abstract or the discussion. This method of calculation 
seems to be unwarranted when the actual IPSS scores, their means and overall changes, 
could be presented. 
The usual method used to present results from a meta-analysis (using forest and funnel 
plots) was not used by the authors. For example, if the outcome of interest is the change in 
IPSS 3 months after the procedure, then (as an example) the results from McVary and 
Cantwell (and others) could be combined. Separately, the results are as follows: 
Table 6 Calculation of 95% CI of mean change after 3 months in IPSS from two studies on PUL 
Paper Mean change (SD) n 95% CI 
McVary -11.1 (7.67) 140 -9.8 to -12.4 
Cantwell -11.1 (7.2) 52 -9.1 to -13.1 
 
Note that Perera et al. (2014) state that a difference in IPSS of 7 points represents a large 
difference. Not only is the mean change in IPSS greater than 7 in both these studies, but the 
whole 95% confidence interval is also greater than 7. Therefore, the results from just these 
two studies indicate a statistically significant and clinically important effect of the procedure 
on the IPSS score (in fact, not only are the mean changes statistically significantly different 
to zero, ruling out the null hypothesis, but they are also significantly different to 7). 
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Note also that the mean change is identical in both studies, although the patients are drawn 
from the same study population. One reason for carrying out a meta-analysis is to see if the 
effect of the treatment is similar in different populations, but the results from the individual 
studies would have to be displayed in order to provide this information. Another reason for 
carrying out a meta-analysis is to combine results from several underpowered studies to 
provide a robust estimation of the effect of a particular treatment. However, in this case, it 
appears that the individual studies have already demonstrated a significant effect 
(statistically and clinically) of the treatment. 
Other (minor) comments 
Most of the studies in the meta-analysis were uncontrolled studies, with a single sham-
control RCT. It may not be appropriate to present effect-size data from non-comparative 
studies in this way, as this type of meta-analysis is typically reserved for two-armed 
randomised trials. 
Heterogeneity is usually expressed using I2, which varies in value between 0 and 100%. 
However, in this study, heterogeneity was expressed in terms of τ2, which is usually used to 
express an estimate of the between-study variance in a random-effects meta-analysis.  
The authors claimed that the mean operative time was comparable over the six patient 
series, but the values stated were 19.1 to 66 minutes, which appears to indicate a large 
difference between studies. 
 
3.9 Additional work carried out by the External Assessment Centre in 
relation to clinical evidence 
EAC literature search  
The EAC designed a search strategy in Medline (Ovid), (Appendix 1) and conducted a search 
of Medline and Medline In-Process. The strategy was adapted for and run in the following 
databases:EMBASE; The Cochrane Library; Pubmed (“epub ahead of print”); National 
Technical Information Service (NTIS) database; NHS Evidence and Web of Science Core 
 
 
Page 41 of 111 
 
MT241 Urolift 
Urolift Assessment Report 
Collection. Citation tracking in Google Scholar of the studies included in the Perera et al. 
(2014) review was also performed.  
The EAC conducted a search of the FDA MAUDE database and of the MHRA Field Safety 
Notices and Medical Device Alerts for adverse events and safety alerts and warnings related 
to Urolift, none were identified. No additional adverse events were detailed in the 
publications found by the EAC. 
The EAC search identified all studies included in the Perera et al. (2014) review as well as 
editorials, conference proceedings and reviews that referenced the sponsor-submitted 
studies (and therefore carried no additional value, and were not included) but no other 
additional studies that met the inclusion criteria were identified. The sponsor also provided 
a more recent two-year follow-up of the LIFT Study by Roehrborn et al. 2014. Expert clinical 
advisers requested long-term data in this Assessment, so these results were incorporated 
into the EAC’s analysis. 
Specifically no comparative studies of Urolift vs. TURP/HoLEP were identified by the EAC, 
which would have more closely fit the NICE scope for this assessment. No additional adverse 
events were detailed in the publications found by the EAC. 
We obtained the Spanish-language manuscript for Abad et al. 2013 and had it professionally 
translated by Languages For Business Ltd. This allowed us to include it in our simplified data 
analysis, using weighted mean changes/improvements from baseline in various outcome 
measures. 
EAC synthesis and analysis 
Due to the lack of transparency in the meta-analysis presented by the Sponsor, the EAC took 
a more simplified approach to the data presented in the studies. Firstly; the following 
publications results were combined, as they reported different aspects of the same series of 
patients: 
1) Chin et al. 2012 and Woo et al. 2012 reported urological and sexual 
function outcomes, respectively, from the same 64-patient case series. 
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2) Roerhborn et al. 2013 and 2014, and McVary 2014 all report on the LIFT 
Study RCT. Roehrborn et al. 2013 reports 12 month urological function 
results, Roerhborn et al. 2014 is a 2-year follow-up report, and McVary 
reports sexual health outcomes for the initial 12 month follow-up on the 
LIFT Study. 
This was important because some of the results may have been double-counted in the 
Perera et al. (2014) meta-analysis, if these publications were not combined into their 
respective studies. 
Roerhborn et al. 2014 was provided by the Sponsor alongside their submission of Perera et 
al. 2014, but not included. Although not a separate study, this does add more long-term 
data (24-month follow-up) to the LIFT RCT, which the EAC felt was of value to the analysis. 
Two clinical advisers also requested long-term clinical data, and therefore this publication 
was included in light of this.  
The EAC were asked to provide comparator data for TURP and HoLEP. In order to achieve 
this, a recent, methodologically-sound systematic review, assessed using a checklist 
designed by the Support Unit for Research Evidence, Cardiff University (Appendix 3), 
comparing TURP and HoLEP was sought out (Li et al. 2014). The source publications 
identified by this review were gathered and relevant outcome data extracted for TURP and 
HoLEP. 
3.9.1 EAC data analysis 
 
Clinically important differences 
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In order to provide the MTAC Committee with some context to judge the results, the EAC 
sought out published minimally important differences in each of the reported outcome 
measures. These are available for questionnaires such as IPSS and IIEF, as they go through a 
validation and testing process during development.  
Where published sources were not available or unsuitable (PVR, for example), the clinical 
experts were surveyed by the EAC for their opinion on the minimum clinically significant 
differences in each outcome reported.  
Published sources 
 IPSS (Barry et al. 1995): 
o Minimum clinically important difference = 3.0 points 
o Moderate difference = 5.1 points 
o Marked difference = 8.8 points  
 BPHII (Barry et al. 1995): 
o Minimum clinically important difference = 0.5 points 
o Moderate difference = 1.1 points 
o Marked difference = 2.2 points  
 IIEF-5 (Rosen et al. 1999):  4 points.  
 
o Note: The authors/developers of IIEF-5 (Rosen et al. 1999) classify erectile 
dysfunction (ED) into five severity grades: no ED (SHIM total score, 22–25), 
mild (17–21), mild to moderate (12–16), moderate (8–11), and severe ED (1–
7). In the published literature, there is no such reported “minimal clinically 
important difference”. The EAC suggested a minimal difference of four 
points, as this would carry a patient from one ED classification to another. 
The majority of clinical experts agreed this was a sensible limit to use for IIEF-
5. 
 Qmax (NICE CG97):  
o Minimum clinically important change = 2ml/s. 
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o “A consensus during a GDG meeting suggested that a change of 2ml/s is 
usually considered as important enough to guide treatment decision. The 
minimal clinical difference was unknown from the patient’s perspective.” 
 
 PVR is assessed by NICE CG97 as having little value as a measure (or diagnostic 
indicator) for LUTS because of poor sensitivity and positive/negative likelihood 
ratios, stating that “elevation of PVR may reflect poor detrusor function as much as 
obstruction”. This was also mentioned to the EAC by one of the specialist clinical 
advisors.  It also does not have questionnaire-style validation, as it is a functional 
urological measurement. 
Table 7 Clinical expert survey for clinical differences 
 Expert 1 Expert 2 Expert 3 
Expert 4 
(drug 
treatments) 
Expert 4 
(surgical 
treatments) 
IPSS 3.00 2.50 3 3 to 5 7 to 15 
IPSS QoL 1.00  2 1 to 1.5 1.5 to 3 
BPHII 2.00   1 to 2 2 to 5 
IIEF 3.00  4 6.00 6.00 
MSHQ-EjD 1.50     
MSHQ-Bother 1.00     
Qmax (ml/s) 2.50 4.00 5  10-15  
PVR (ml)   50   
 
Blank spaces indicate that a reply was not received, or the expert did not know/was unable 
to give a clinically significant difference for the outcome measure. 
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Outcome measures overview – EAC calculations 
Table 8 collates all EAC-calculated outcome measures (using weighted means) published 
studies in the sponsor’s submission, as a quick results overview. The outcomes reported are 
IPSS, IPSS QoL, BPHII, IIEF, MSHQ-EjD, MSHQ-Bother, Qmax and PVR. This is shown for 1, 3, 
12 and 24 month follow-up points, as reported. Each individual outcome measure has its 
own table below that, with individual studies reporting changes from baseline, the number 
of patients in the study, and significance values (p).  
 
Table 8 Overview of EAC-calculated results at 1, 3, 12 and 24 months post-Urolift from 
baseline (from studies in the Perera et al. (2014) meta-analysis) 
 1 month 3 month 12 month 24 month 
IPSS 
(Negative score is 
improvement) 
-10.35 -11.82 -10.49 -9.22 
IPSS QoL 
(Negative score is 
improvement) 
-2.27 -2.48 -2.31 -2.22 
BPHII 
(Negative score is 
improvement) 
-3.29 -3.96 -3.95 -3.76 
IIEF 
(Positive score is 
improvement) 
0.52 1.34 0.80  
MSHQ-EjD 
(Negative score is 
improvement) 
1.82 1.47 0.83  
MSHQ-Bother 
(Negative score is 
improvement) 
-0.67 -0.79 -0.91  
Qmax 
(Positive is 
improvement) 
4.16 3.78 3.52 4.15 
PVR 
(Negative is 
improvement) 
-7.00 -10.34 -5.72  
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Outcome measures from all studies 
The tables below show mean changes from baseline for each study (Abad et al., 2013; 
Cantwell et al., 2013; Chin et al. 2012 and Woo et al. 2012 combined cohort study; LIFT 
combined study results (Roerhborn et al. 2013 and 2014 and McVary 2014), McNicholas et 
al. 2013; Shore et al. 2014 and Woo et al. 2011), with the number of patients in the analysis, 
mean results and weighted mean results at 1, 3, 12 and 24 months, where  reported. 
IPSS score: IPSS scores were widely reported and mean improvements from baseline over 
12 months ranged from -9.22 to -11.59 points. All improvements were statistically 
significant where reported. A higher score is worse, so negative score means a symptom 
improvement. 
 
Table 9 Mean difference changes in IPSS score in each included study 
 IPSS Change from baseline: mean ±SD, (n, p value) 
Study 1 month 3 month 12 month 24 month 
Abad 2013 
(no SDs reported for 
mean change) 
-10 
(n=20) 
p=0.001) 
-9.9 
(n=17 
p<0.001) 
-11 
(n=9 
p=0.008) 
 
Cantwell 2013 -10.9±6.9 
(n=53 
p<0.001) 
-11.1±7.2 
(n=52 
p<0.001) 
-8.7±7.5 
(n=48 
p<0.001) 
 
Chin and Woo 2012 
(no SDs reported for 
mean change) 
 -13.6 
(n=62 
p<0.001) 
-10.4 
(n=55 
p<0.001) 
 
LIFT Study -9.91±7.08 
(n=138 
p<0.001) 
-11.13±7.68 
(n=139 
p<0.001) 
-10.63±7.44 
(n=126 
p<0.001) 
-9.22±7.57 
(n=106 
p<0.001) 
McNicholas 2013 
(no SDs reported for 
mean change) 
-10.7 
(n=95 
p<0.001) 
-12.6 
(n=82 
p<0.001) 
-12.3 
(n=51 
p<0.001) 
 
Shore 2014 -10.47±7.35 
(n=51 
p<0.001) 
   
Woo 2011  -11.2±5.7 
(n=15 
p<0.001) 
-8.6±7.8 
(n=13 
p=0.002) 
 
Mean -10.396 -11.58833333 -10.27166667 -9.22 
Weighted mean -10.3522409 -11.81735695 -10.48701987 -9.22 
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IPSS QoL: IPSS QoL score mean improvements from baseline ranged from -2.22 to -2.584 
points. All improvements were statistically significant where reported. This is to be 
expected, as QoL is a sub-question of the IPSS, so where IPSS improvement is seen in the 
table above, there should also be a corresponding QoL improvement. A higher score is 
worse, so negative score means a symptom improvement. 
Table 10 Mean difference changes in IPSS QoL in each included study 
 
 
 
 
 
 
 
 
 
 
 
 IPSS QoL change from baseline: mean ±SD, (n) 
Study 1 month 3 month 12 month 24 month 
Abad 2013     
Cantwell 2013 -2.2±1.8 
(n=53 
p<0.001) 
-2.3±1.7 
(n=52 
p<0.001) 
-2.0±1.7 
(n=48 
p<0.001) 
 
Chin and Woo 2012 
(no SDs reported for 
mean change) 
 -2.8 
(n=62 
p<0.001) 
-2.4 
(n=55 
p<0.001) 
 
LIFT Study -2.01±1.74 
(n=138 
p<0.001) 
-2.22±1.78 
(n=139 
p<0.001) 
-2.3±1.59 
(n=126 
p<0.001) 
-2.22±1.71 
(n=106 
p<0.001) 
McNicholas 2013 
(no SDs reported for 
mean change) 
-2.9 
(n=138 
p<0.001) 
-2.8 
(n=65 
p<0.001) 
-2.6 
(n=43 
p<0.001) 
 
Shore 2014 -2.12±1.94 
(n=51 
p=0.001) 
   
Woo 2011  -2.8±1.7 
(n=15 
p<0.001) 
-2.2±1.9 
(n=13 
p<0.001) 
 
Mean -2.3075 -2.584 -2.3 -2.22 
Weighted mean -2.266031746 -2.47981982 -2.30947 -2.22 
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BPHII: BPHII score mean improvements from baseline ranged from -3.384 to -3.854 points. 
All improvements were statistically significant where reported. A higher score is worse, so 
negative score means a symptom improvement. 
 
Table 11 Mean difference changes in BPHII in each included study 
 BPHII change from baseline: mean ±SD, (n) 
Study 1 month 3 month 12 month 24 month 
Abad 2013 
(no SDs reported for 
mean change) 
-3.3 
(n=20 
p=0.001) 
-3.1 
(n=17 
p=0.001) 
-3.4 
(n=9 
p=0.006) 
 
Cantwell 2013 -3.1±3.3 
(n=53 
p<0.001) 
-3.3±2.9 
(n=52 
p<0.001) 
-3.1±3.1 
(n=48 
p<0.001) 
 
Chin and Woo 2012 
(no SDs reported for 
mean change) 
 -4.6 
(n=53 
p<0.001) 
-4.1 
(n=46 
p<0.001) 
 
LIFT Study -2.81±3.46 
(n=138 
p<0.001) 
-3.96±3.21 
(n=139 
p<0.001) 
-3.97±3.26 
(n=126 
p<0.001) 
-3.76±3.45 
(n=106 
p<0.001) 
McNicholas 2013 
(no SDs reported for 
mean change) 
-4.3 
(n=68 
p<0.001) 
-4.2 
(n=65 
p<0.001) 
-4.7 
(n=47 
p<0.001) 
 
Shore 2014 -3.41±3.57 
(n=51 
p<0.001) 
   
Woo 2011     
Mean -3.384 -3.832 -3.854 -3.76 
Weighted mean -3.28603 -3.961779141 -3.94609 -3.76 
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IIEF: IIEF score mean changes ranged from +0.483333 to +1.4 points. The majority of 
changes from baseline were positive, indicating a symptom improvement (a better score 
indicates better sexual function). However, many of the measurements were not statistically 
significant, which supports the claim that Urolift does not affect sexual function, and no 
results indicated a worsening of sexual function post-Urolift. 
Table 12 Mean difference changes in IIEF score in each included study 
 IIEF change from baseline: mean ±SD, (n) 
Study 1 month 3 month 12 month 24 month 
Abad 2013     
Cantwell 2013 0.5±4.6 
(n=34 
p=0.51) 
0.7±9.2 
(n=40 
p=0.66) 
0.9±5.7 
(n=33 
p=0.30) 
 
Chin and Woo 2012 
(no SDs reported for 
mean change) 
 2.2 
(n=33 
p=0.004) 
1.8 
(n=26 
p=0.01) 
 
LIFT Study 
(no SDs reported for 
mean change) 
0.6 
(77 
p=0.309) 
1.3 
(80 
p=0.021) 
0.4 
(73 
p=0.013) 
 
McNicholas 2013     
Shore 2014 0.35±4.76 
(n=34 
p=0.67) 
   
Woo 2011     
Mean 0.483333 1.4 1.033333  
Weighted mean 0.517931 1.337255 0.800758  
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MSHQ-EjD:  MHSQ-EjD score mean changes ranged from +0.466667 to +1.696667 points. All 
changes from baseline were positive, indicating a symptom improvement (a higher score 
indicates better sexual function). Some of the changes from baseline were statistically 
significant and others were not, however there was only a mean worsening of MHSQ-EjD 
scores in one time-point of one study (12 month follow-up, Chin and Woo et al. 2012), 
which does not change the overall mean improvement or weighted mean improvement 
seen across studies. 
Table 13 Mean difference changes in MSHQ-EjD in each included study 
 MSHQ-EjD change from baseline: mean ±SD, (n) 
Study 1 month 3 month 12 month 24 month 
Abad 2013     
Cantwell 2013 1.4±2.3 
(n=34 
p<0.001) 
0.3±4.6 
(n=39 
p=0.98) 
0.8±2.8 
(n=33 
p=0.62) 
 
Chin and Woo 2012 
(no SDs reported 
for mean change) 
 1.6 
(n=28 
p<0.001) 
-0.7 
(n=22 
p=0.7) 
 
LIFT Study 
(no SDs reported 
for mean change) 
2.1 
(n=77 
p<0.001) 
1.8 
(n=80 
p<0.001) 
1.3 
(n=75 
p<0.001) 
 
McNicholas 2013     
Shore 2014 1.59±2.75 
(n=34 
p=0.002) 
   
Woo 2011     
Mean 1.696667 1.366667 0.466667  
Weighted mean 1.816276 1.470068 0.834615  
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MSHQ-Bother: MSHQ-Bother score mean changes from baseline over 12 months ranged 
from -0.65333 to -0.76667 points. A higher score is worse, so negative score means an 
improvement. Some of the changes from baseline were statistically significant and others 
were not. None of the results indicated a worsening of sexual function post-Urolift. 
Table 14 Mean difference changes in MSHQ-Bother in each included study 
 MSHQ-Bother change from baseline: mean ±SD, (n) 
Study 1 month 3 month 12 month 24 month 
Abad 2013     
Cantwell 2013 -0.5±1.1 
(n=34 
p=0.008) 
-0.4±2.3 
(n=37 
p=0.44) 
-0.4±1.4 
(n=33 
p=0.23) 
 
Chin and Woo 2012 
(no SDs reported 
for mean change) 
 -0.7 
(n=28 
p<0.001) 
-0.7 
(n=22 
p=0.002) 
 
LIFT Study 
(no SDs reported 
for mean change) 
-0.7 
(n=77 
p<0.001) 
-1 
(n=80 
p<0.001) 
-1.2 
(n=75 
p<0.001) 
 
McNicholas 2013     
Shore 2014 -0.76±1.39 
(n=34 
p=0.003) 
   
Woo 2011     
Mean -0.65333 -0.7 -0.76667  
Weighted mean -0.66717 -0.78897 -0.91231  
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Qmax: Qmax mean improvements from baseline ranged from +3.456 to +4.166666667 ml/s. 
All improvements were statistically significant where reported, with p<0.05, so the evidence 
supports Urolift’s ability to increase maximum urine flow rates. 
Table 15 Mean difference changes in Qmax in each included study 
 Qmax ml/s change from baseline: mean ±SD, (n) 
Study 1 month 3 month 12 month 24 month 
Abad 2013 
(no SDs reported 
for mean change) 
4.5 
(n=20 
p=0.006) 
4.8 
(n=17 
p=0.003) 
4.2 
(n=9 
p=0.042) 
 
 
Cantwell 2013  2.5±5.3 
(n=40 
p=0.002) 
2.5±5.0 
(n=37 
p=0.005) 
 
 
Chin and Woo 2012 
(no SDs reported 
for mean change) 
 2.4 
(n=46 
p<0.001) 
2.6 
(n=39 
p<0.001) 
 
 
LIFT Study  4.24±5.13 
(n=124 
p<0.001) 
3.98±4.92 
(n=105 
p<0.001) 
4.15±5.05 
(n=98 
p<0.001) 
McNicholas 2013 
(no SDs reported 
for mean change) 
4.7 
(n=67 
p<0.001) 
4.3 
(n=80 
p<0.001) 
4 
(n=41 
p<0.001) 
 
 
Shore 2014 3.3±4.5 
(n=50 
p<0.001) 
   
 
Woo 2011     
 
Mean 4.166666667 3.648 3.456 4.15 
Weighted mean 4.159854015 3.784234528 3.522077922 4.15 
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PVR: PVR changes from baseline ranged from -3.0575 to -10.55 mls. No changes were 
statistically significant.  
Table 16 Mean difference changes in PVR in each included study 
 PVR ml change from baseline: mean ±SD, (n) 
Study 1 month 3 month 12 month 24 month 
Abad 2013     
Cantwell 2013 
(no SDs reported 
for mean change) 
 -13.23 
(n=51 
p=0.241) 
-11.23 
(n=46 
p=0.262) 
 
Chin and Woo 2012 
(no SDs reported 
for mean change) 
 -4 
(n=61 
p=0.7) 
8 
(n=8 
p=0.4) 
 
LIFT Study 
(no SDs reported 
for mean change) 
 -11 
(n=137 
p=0.146) 
-12 
(n=120 
p=0.1111) 
 
McNicholas 2013 
(no SDs reported 
for mean change) 
-7 
(n=48 
p=0.775) 
-14 
(n=41 
p=0.082) 
3 
(n=29 
p=0.299) 
 
Shore 2014     
Woo 2011     
Mean -7 -10.55 -3.0575  
Weighted mean -7 -10.3386 -5.71832  
 
Note: In order to utilise the results from as many of the studies as possible, results here are not 
displayed with 95% CIs (This is not done above due to inconsistent reporting of SDs). In Appendix 2 
we present these results with 95% CIs.  
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Comparison with sham control at 3 months (t-test) (from Roerhborn et al. 2013) 
The table below is taken from the LIFT Study RCT, comparing Urolift implants to the sham 
procedure, which involves rigid cystoscopy. This is the only comparative data available for 
Urolift, and the EAC feels it is of value, as there is a known “sham effect” (Roerhborn et al. 
2013) where there is an improvement in IPSS and BPHII after the sham treatment. This is 
seen below in the “Control ITT group), as there is some improvement in these measures. 
The authors recognise this phenomenon and attribute to a combination of placebo, dilation 
and regression. However, most importantly, it is only around half of the improvement seen 
with Urolift; with a statistically significant difference from sham control improvements. 
Sexual health measures are not significantly different, which supports the Sponsor’s claims 
that Urolift does not affect sexual function in these patients. 
Table 17 Intention-to-treat comparison of Urolift and sham control from Roerhborn et al. 
(2013) 
 Urolift-ITT group. Mean±SD (n) Control ITT group. Mean±SD (n)  
 Baseline 3 months Change Baseline 3 months Change p Value 
IPSS 
22.2±5.48 
(140) 
11.2± 7.65 -11.1±7.67 
24.4±5.75 
(66) 
18.5±8.59 -5.9±7.66 0.003 
IPSS QoL 
4.6±1.1 
(140) 
2.4±1.7 -2.2±1.8 
4.7±1.1 
(66) 
3.6±1.6 -1.0±1.5 0.005 
BPHII 
6.9±2.8 
(140) 
3.0±3.1 -3.9±3.2 
7.0±3.0 
(66) 
4.9±3.2 -2.1±3.3 <0.001 
IIEF 
13.3±8.4 
(132) 
13.4±9.2 0.1±5.8 
13.7±8.5 
(65) 
15.2±8.5 1.5±6.4 0.139 
MSHQ-
EjD 
8.7±3.1 
(94) 
10.9±3.2 2.2±2.5 
8.8±3.1 
(50) 
10.5±3.5 1.7±2.6 0.283 
MSHQ-
Bother 
2.4±1.7 
(117) 
1.6±1.7 -0.8±1.5 
2.2±1.7 
(60) 
1.5±1.7 -0.7±1.6 0.595 
Qmax 
ml/s 
8.02±2.43 
(126) 
12.29±5.4 4.28±5.16 
7.93±2.41 
(56) 
9.91±4.29 1.98±4.88 0.005 
PVR ml 
85.5±69.2 
(140) 
75.8±83.9 -9.7±85.5 
85.6±70.8 
(65) 
63.4±64.0 -22.2±70.7 0.306 
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TURP and HoLEP Comparator data 
Note: These “comparative” results must be considered carefully. There are no 
comparative studies with Urolift vs TURP or HoLEP, and therefore the patient populations 
may vary and outcome measure improvement e.g. IPSS scores, are highly dependent upon 
the patients’ baseline scores. These numbers are provided by the EAC in order to provide 
some comparative context to the MTAC committee. 
None of the studies in the sponsor’s submission are comparative with TURP or HoLEP, as 
requested in the NICE scope document, and no such studies were identified by the EAC in 
our independent literature search. Therefore, the EAC performed a rapid pragmatic data 
synthesis in order to provide some comparative outcome data for these technologies. 
The EAC’s solution was to find a TURP vs HoLEP systematic review, and extract relevant 
outcome data from their identified sources. A systematic review search led to the selection 
of a review by Li et al. 2014, for the following reasons: 
 This is a very recent systematic review, published in July 2014, and contains the most 
recent RCTs – namely a paper by Sun et al., also published in 2014. 
 The protocol for this review is published on the PROSPERO website at The University 
of York Centre for Reviews and Dissemination (CRD) – protocol number 
CRD42014007334 
  Baseline patient characteristics (age, prostate volume, IPSS score and Qmax) are 
similar to those seen in the Urolift studies in the sponsor’s submission: 
Table 18 Baselines comparison between Urolift studies and TURp vs HoLEP RCTs from Li et 
al. (2014) 
Outcome measure Urolift studies TURP/HoLEP RCTs 
Age (years) 64 - 74 65.1 - 72.2 
IPSS 21.45 - 26.7 21.9 - 26.4 
Prostate volume (mls) 41.3 - 51 36.5 - 77.8 
Qmax (ml/s) 6.9 – 8.85 4.9 - 8.9 
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The patient age and IPSS baselines all fall within the same range. The prostate volume range 
is wider in the TURP/HoLEP RCT studies, particularly skewed slightly towards men with 
larger prostates. Similarly, the Qmax baselines are skewed slightly towards slower flow rates 
in the baselines of the TURP/HoLEP RCTs. 
The EAC critically appraised the systematic review (Li et al. 2014) using a checklist designed 
by the Support Unit for Research Evidence, Cardiff University. 
Results are presented as weighted mean changes from baseline. Negative IPSS, IPSS QoL and 
PVR results represent an improvement from baseline. Positive Qmax results represent an 
improvement from baseline. The number of studies contributing to the weighted mean 
results is shown in brackets. 
Table 19 Notes on TURP vs HoLEP RCT studies identified by Li et al. (2014) 
Study Notes 
Ahyai et al 2007 Replaces Kuntz et al. 2004, as this contains 2-year follow-up results. 
Eltabey et al 2010  
Gilling et al 1999 4 year results published, but not usable – dropout rates not reported for 
each patient group. 
Gupta et al 2006  
Mavuduru et al 2009 Only reports results up to 9 months post-procedure. 
Montorsi et al 2004  
Sun et al 2014  
Tan et al  2 year and 7 year results published, but not usable – dropout rates not 
reported for each patient group. 
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Table 20 EAC-calculated TURP and HoLEP improvements in mean from baselines 
TURP Weighted mean change from baseline (number of studies reporting) 
 
1 month 3 month 12 month 24 month 
IPSS -17.34 (5) -19.70 (2) -18.13 (7) -17.50 (1) 
IPSS QoL -2.99 (3) -2.80 (1) -3.18 (4) NR (0) 
Qmax 14.58 (5) 14.11 (2) 16.69 (7) 23.20 (1) 
PVR -137.43 (3) -89.34 (1) -127.29 (3) -196.10 (1) 
     
     
HoLEP Weighted mean change from baseline (number of studies reporting) 
 
1 month 3 month 12 month 24 month 
IPSS -17.68 (5) -20.88 (2) -19.29 (7) -20.40 (1) 
IPSS QoL -2.64 (3) -3.00 (1) -3.24 (4) NR (0) 
Qmax 15.29 (5) 18.25 (2) 17.78 (7) 23.10 (1) 
PVR -160.23 (3) -78.00 (1) -161.47 (3) -231.40 (1) 
 
Notes on these comparative outcome results: 
 Both TURP and HoLEP give much better improvement in IPSS scores (including QoL, 
as these scores are linked) at all time-points:  
o Urolift: -9.22 to -11.82  
o TURP: -17.34 to -19.70 
o HoLEP: -17.68 to -20.88 
 Qmax improvements are also higher at all time points with both TURP and HoLEP: 
o Urolift: +3.53 to +4.16 ml/s 
o TURP: +14.11 to +23.20 ml/s 
o HoLEP:  +15.29 to +23.10 ml/s  
 TURP and HoLEP also give better improvements in PVR, but this is less widely 
reported in both the Urolift studies and the TURP/HoLEP studies. It may be worth 
noting that one Specialist Clinical Adviser questioned the importance of PVR as an 
outcome measure for Urolift, and presumably other surgical treatments for BPH 
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 BPHII scores are not reported in the TURP and HoLEP studies, but as a prostate 
symptom score, it should give general improvements in agreement with IPSS scores. 
IPSS is the standard measure of BPH symptom improvement, which may explain the 
lack of BPHII results with TURP and HoLEP 
 Sexual function is poorly reported in the TURP and HoLEP papers (their aim is 
symptom improvement, so sexual function is secondary, and a complication), and 
therefore it is difficult to ascertain the impact of these interventions on erectile and 
ejaculatory function 
o A clinical adviser pointed out that it is difficult to get reliable data on erectile 
function for the comparator interventions, but recommended the GOLIATH 
Study (Bachmann et al. 2015) for IIEF-5 reporting post-TURP up to 12 months. 
GOLIATH patients were measured as 13.7±7.2 at baseline, and 14.1±8.2 at 12 
months post-TURP, showing no significant changes in a cohort of 119 
patients. 
o Two further clinical advisers stated a 5% rate for new erectile dysfunction 
and 70-80% retrograde ejaculation rate, post-TURP. 
o One clinical advisor recommended the 6-year follow-up on HoLEP by Gilling 
et al. (2008) for sexual function post-HoLEP; and a 76% retrograde 
ejaculation rate is reported, which is similar to that quoted by our clinical 
experts for TURP. IIEF improvement from baseline is not reported. 
 
 Complications and procedural data from all Urolift studies 
Complications are reported in detail as in all publications. As with outcome data, complications were collated where multiple studies reported 
on the same patient cohort e.g. the three LIFT study papers. Complications are quantified per study and presented as percentages of total 
patients, with an overall and 95% CI for each. Complications are grouped according to type: pain and sexual complications, urological, and 
other (including infections). Procedural data is presented below complications. 
Table 21 Urolift complications; pain, haematuria, sexual function 
Study 
Sample 
size 
Erectile 
dysfunction 
Retrograde 
ejaculation 
Dysuria Haematuria 
Irritative 
symptoms 
Penile pain Pelvic pain/discomfort Unspecified pain 
  
n % n % n % n % n % n % n % n % 
Abad et al. 2013 20 0 0% 0 0% 14 70% 6 30% 8 40% 
      
Cantwell et al. 2013 53 0 0% 0 0% 20 38% 14 26% 
    
11 21% 
  
Chin et al. 2012 
and Woo et al. 2012 
64     
            
LIFT Study 140 0 0% 0 0% 49 35% 37 26% 
    
27 19% 
  
McNicholas et al. 
2013 
102     25 25% 16 16% 
        
Shore et al. 2014 51     27 53% 38 75% 
  
2 4% 8 16% 
  
Woo et al. 2011 19 2 11%   11 58% 12 63% 9 47% 1 5% 1 5% 1 5% 
Overall (95% CI) 
 
 
1%  
(0% to 
2%) 
 
0%  
(0% to 
1%) 
 
38% 
(25% to 
51%)  
31% 
(27% 
to 
36%) 
 
44%  
(29% to 
60%) 
 
5%  
(1% to 
11%) 
 
18%  
(14% to 23%)  
5%  
(1% to 25%) 
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Table 22 Urolift complications; urological 
Study Sample size Weak stream 
Urinary 
frequency 
Urine flow 
decreased 
Incontinence Retention Urgency Spraying Incomplete voiding 
  
n % n % n % n % n % n % n % n % 
Abad et al. 2013 20 
        
2 10% 
      
Cantwell et al. 2013 53 
      
2 4% 4 8% 7 13% 
    
Chin et al. 2012 
and Woo et al. 2012 
64 
                
LIFT Study 140 
      
6 4% 1 1% 13 9% 
    
McNicholas et al. 2013 102 
        
3 3% 10 10% 
    
Shore et al. 2014 51 
  
0 0% 0 0% 2 4% 3 6% 4 8% 
    
Woo et al. 2011 19 1 5% 
    
3 16% 3 16% 
  
2 11% 1 5% 
Overall (95% CI) 
  
5% 
(1% to 25%)  
0% 
(0 to 7%)  
0% 
(0 to 7%)  
5% 
(3% to 8%)  
4% 
(2% to 6%) 
  
10%  
(7% to 4%)  
11% 
(3% to 
31%)  
5% (1% to 
25%) 
 
Table 23 Urolift complications; other 
Study Sample size Bladder spasm Prostatitis Orchitis/ epidiymitis Urinary tract infection Rigor 
  
n % n % n % n % n % 
Abad et al. 2013 20 
    
1 5% 
    
Cantwell et al. 2013 53 3 6% 
        
Chin et al. 2012 and Woo 
et al. 2012 
64 
  
1 2% 1 2% 7 11% 1 2% 
LIFT Study 140 6 4% 
    
4 3% 
  
McNicholas et al. 2013 102 
    
3 3% 3 3% 
  
Shore et al. 2014 51 
          
Woo et al. 2011 19 3 16% 1 5% 
  
1 5% 
  
Overall (95% CI) 
  
6% 
(3% to 9%)  
4% 
(1% to 10%)  
3% 
(1% to 6%)  
5% 
(3% to 7%)  
2% 
(0% to 8%) 
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Table 24 Urolift complications; procedural data 
Study 
Sample 
size 
Reoperation rate 
Procedure time 
(mins)
 
 
Local anaesthesia 
Return to 
normal 
activity 
(days) 
Catheter required 
Catheter 
duration 
(hrs)
 1
 
Encrusted implants 
Encrusted implants 
removed 
  
n % mean SD n % mean SD n % mean SD n % n % 
Abad et al. 2013 20 1 5% 19.1 
 
0 0% 
  
2 10% 
  
0 0% 
  
Cantwell et al. 2013 53 1 2% 53 15.0 46 87% 6.5 6.8 26 49% 33 
     
Chin et al. 2012 
and Woo et al. 2012 
64 13 20% 
      
34 53% 20 
 
0 0% 
  
LIFT Study 140 11 8% 66.2 23.8 139 99% 8.6 7.5 40 29% 21.6 
 
10 7% 6 4% 
McNicholas et al. 2013 102 4 4% 57.8 15.8 
    
54 53% 
      
Shore et al. 2014 51 
  
52 22.0 50 98% 5.1 5.8 10 20% 16 
     
Woo et al. 2011 19 3 16% 
      
13 68% 
  
0 0% 
  
Overall (95% CI) 
  
8%  
(5% to 11%) 
59.6 
(57.5-61.7) 
20.2 
 
93%  
(89% to 
96%) 
7.4 
(6.7-
8.2) 
5.9 
 
39%  
(35% to 44%) 
22.3 
  
3% (1% to 6%) 
 
4% (2% to 9%) 
 
 
1Catheter duration was not always reported with SDs, so 95% CIs could not be calculated. 
 
Length of stay data was only reported by Abad et al. 2013, at 2.6 hrs (range 3-72). Otherwise, Shore et al. report “All patients were treated as day cases, 
there were no overnight stays”, but this is not quantifiable.  
 
It is also worth noting the 100% general anaesthesia use by Abad et al. in their protocol, and the markedly shorter procedure time. This may be a facet of 
having a patient under general anaesthetic, but the publication does not clarify this. However, the shorter procedure time in the Abad et al. (2013) study 
does not impact the weighted mean greatly due to the low patient number in this case series. The EAC asked clinical advisers about Urolift procedure times, 
and many said that it could be done in 30 minutes (from their own practical experience), and that 60 minutes was under “trial conditions”. 
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Complications and procedural data from all TURP vs HoLEP studies 
Table 25 TURP complications; pain, haematuria, sexual function 
Study Sample size Dysuria Irritative symptoms 
  
n % n % 
Ahyai et al 2007 88 
    
Eltabey et al 2010 40 
  
8 20% 
Gilling et al 1999 59 
    
Gupta et al 2006 50 1 2% 
  
Mavuduru et al 2009 15 3 20% 
  
Montorsi et al 2004 48 13 27% 
  
Sun et al 2014 82 
    
Tan et al 2003 30 
    
Overall (95% CI) 
  
13% (0% to 36%) 
 
20% (10% to 35%) 
 
Table 26 TURP complications; urological 
Study Sample size Incontinence Retention 
  
n % n % 
Ahyai et al 2007 100 1 1% 
  
Eltabey et al 2010 40 12 30% 
  
Gilling et al 1999 59 1 2% 
  
Gupta et al 2006 50 
    
Mavuduru et al 2009 15 0 0% 
  
Montorsi et al 2004 48 18 38% 1 2% 
Sun et al 2014 82 
    
Tan et al 2003 30 11 37% 
  
Overall (95% CI) 
  
11% (0% to 30%)  2% (0% to 11%) 
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Table 27 TURP complications; other 
Study Sample size 
Urinary tract 
infection 
Transfusion TUR Syndrome 
Bladder neck 
contracture 
Urethral stricture BPH recurrence 
  
n % n % n % n % n % n % 
Ahyai et al 2007 100 
  
2 2% 
  
3 3% 3 3% 0 0% 
Eltabey et al 2010 40 
  
3 8% 
    
2 5% 
  
Gilling et al 1999 59 
  
4 7% 
    
6 10% 
  
Gupta et al 2006 50 
  
1 2% 1 2% 
  
2 4% 
  
Mavuduru et al 2009 15 
  
1 7% 
        
Montorsi et al 2004 48 
    
1 2% 
  
4 8% 
  
Sun et al 2014 82 
   
11% 
 
21% 
  
4 5% 
  
Tan et al 2003 30 2 7% 1 3% 
    
2 7% 
  
Overall (95% CI) 
  
7% (2% to 21%) 
 
6% (4% to 8%) 
 
9% (0% to 24%)  3 (1% to 8%) 
 
6% (4% to 9%) 0% (0% to 4%) 
 
Table 28 TURP complications; procedural data 
Study Sample size Reoperation rate Procedure time (mins) Length of stay (hrs) Catheter required Catheter duration (hrs) 
  
n % mean SD mean SD n % mean SD 
Ahyai et al 2007 100 7 7% 73.8 24.00 85.8 39.10 5 5% 43.4 21.10 
Eltabey et al 2010 40 
  
73.6 22.30 91.2 38.40 
  
50.4 26.40 
Gilling et al 1999 59 4 7% 
  
47.5 17.37 8 14% 37.2 15.92 
Gupta et al 2006 50 
  
64.1 13.10 
  
3 6% 45.7 12.70 
Mavuduru et al 2009 15 
  
43 9.36 
  
1 7% 78.2 17.84 
Montorsi et al 2004 48 1 2% 57 15.00 85.8 18.90 
  
57.78 17.50 
Sun et al 2014 82 
  
62.91 27.52 283.68 81.84 
  
127.43 75.93 
Tan et al 2003 30 2 7% 
  
49.9 5.60 4 13% 44.9 5.60 
Overall (95% CI) 
  
6% (4% to 10%) 65.9 16.4 122.3 47.2 
 
8% (5% to 12%) 62.7 37.4 
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Table 29 HoLEP complications; pain, haematuria, sexual function 
Study Sample size Dysuria Irritative symptoms 
  
n % n % 
Ahyai et al 2007 100 
    
Eltabey et al 2010 40 
  
10 25% 
Gilling et al 1999 61 
    
Gupta et al 2006 50 5 10% 
  
Mavuduru et al 2009 15 1 7% 
  
Montorsi et al 2004 52 33 63% 
  
Sun et al 2014 82 
    
Tan et al 2003 30 
    
Overall (95% CI) 
  
31% (0% to 80%) 
 
25% (14% to 40%) 
 
Table 30 HoLEP complications; urological 
Study Sample size Incontinence Retention 
  
n % n % 
Ahyai et al 2007 100 1 1% 
  
Eltabey et al 2010 40 8 20% 
  
Gilling et al 1999 61 
    
Gupta et al 2006 50 1 2% 
  
Mavuduru et al 2009 15 2 13% 
  
Montorsi et al 2004 52 26 50% 3 6% 
Sun et al 2014 82 
    
Tan et al 2003 30 15 50% 
  
Overall (95% CI) 
  
14% (0% to 38%)  2% (0% to 11%) 
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Table 31 HoLEP complications; Other 
Study Sample size 
Urinary tract 
infection 
Transfusion TUR Syndrome 
Bladder neck 
contracture 
Urethral stricture BPH recurrence 
  
n % n % n % n % n % n % 
Ahyai et al 2007 100 
      
3 3% 4 4% 1 1% 
Eltabey et al 2010 40 
  
0 0% 
    
1 3% 
  
Gilling et al 1999 61 3 5% 0 0% 
    
6 10% 
  
Gupta et al 2006 50 
  
0 0% 
    
1 2% 
  
Mavuduru et al 2009 15 
            
Montorsi et al 2004 52 
    
0 0% 
  
1 2% 
  
Sun et al 2014 82 
   
1% 
 
6% 
  
3 4% 
  
Tan et al 2003 30 0 0% 0 0% 
    
1 3% 
  
Overall (95% CI) 
  
3% (0% to 8%) 
 
1% (0% to 2%) 
 
3% (0% to 12%)  3% (1% to 8%) 
 
4% (3% to 7%)   1% (0% to 5% 
 
Table 32 HoLEP complications; procedural data 
Study Sample size Reoperation rate Procedure time (mins) Length of stay (hrs) Catheter required Catheter duration (hrs) 
  
n % mean SD mean SD n % mean SD 
Ahyai et al 2007 100 
 
7% 94.6 35.10 53.3 15.90 0 0% 27.6 10.40 
Eltabey et al 2010 40 
  
72.8 21.70 62.4 28.80 
  
36 33.60 
Gilling et al 1999 61 1 2% 
  
26.1 11.71 5 8% 20 11.39 
Gupta et al 2006 50 
  
75.4 22.80 
  
2 4% 28.6 20.50 
Mavuduru et al 2009 15 
  
53 9.84 
  
1 7% 46.42 14.25 
Montorsi et al 2004 52 1 2% 74 19.50 59 19.90 
  
31 13.00 
Sun et al 2014 82 
  
70.17 29.51 272.88 94.32 
  
113.63 50.61 
Tan et al 2003 30 0 0% 
  
27.6 2.70 5 17% 17.7 2.70 
Overall (95% CI) 
  
4% (2% to 7%) 72.1 20.5 97.8 47.4 
 
4% (0% to 11%) 44.2 26.8 
 Notes on complications comparison between Urolift, TURP and HoLEP studies 
As with the clinical outcome measures being compared earlier, these results should be 
interpreted cautiously and in knowledge that there are no true comparative studies 
between Urolift and TURP or HoLEP. One weakness of this type of comparative approach is 
that the Urolift studies report a different set of complications than those reported for TURP 
vs HoLEP RCTs, and with good reason:  Urolift complications seem to be typically mild, such 
as transient dysuria or haematuria. Presumably, dysuria and haematuria are expected 
occurrences with TURP and HoLEP. Therefore, these are not as widely reported in the TURP 
vs HoLEP RCTs, in part due to them being so normal and their mild nature. Similarly, implant 
encrustation is not an event that can occur with TURP or HoLEP, but where seen, the 
implants can easily be removed with forceps without further issue. This was largely 
supported by when the EAC asked the clinical advisers, and the majority did not see implant 
encrustation as a significant issue. 
Other complications comparisons (of those most widely reported): 
 Incontinence was less prevalent with Urolift (5%, CI 3% to 8%) compared to TURP 
(11%, CI 0% to 30%) and HoLEP (14%, CI 0% to 38%) 
 Reoperation rates were slightly higher with Urolift (8%, CI 5 % to 11%) compared to 
TURP 4% (2% to 7%) and HoLEP (6%, CI 4% to 10%) 
 Procedure time is shorter with Urolift (59.6 mins ± 20.2) compared to TURP (72.1 
mins ± 20.5) and HoLEP (65.9 mins ± 16.4). The EAC asked clinical advisers about the 
Urolift procedure time, in their experience. The majority said that the procedure 
could be done in 30 minutes, and that 60 minutes was under “trial conditions”. 
Additional notes: 
 Length of stay was poorly reported in the Urolift studies, which means a comparison 
cannot be made to TURP and HoLEP. The EAC asked clinical advisers about the 
Urolift length of stay, and the majority said that it was done as a daycase procedure, 
with very few patients needing an overnight stay. 
 
 
Page 67 of 111 
 
MT241 Urolift 
Urolift Assessment Report 
 Erectile function, urinary tract infection, prostatitis, orchitis and bladder spasm were 
poorly reported in the TURP vs HoLEP RCTs, which means a comparison cannot be 
made to Urolift.  The EAC asked the clinical experts about this: 
o One clinical adviser pointed out that it is difficult to get reliable data on 
erectile function for the comparator interventions, but recommended the 
GOLIATH Study (Bachmann et al. 2015) for IIEF-5 reporting post-TURP up to 
12 months. GOLIATH patients showed no significant changes in IIEF-5 post-
TURP. 
o Two further clinical advisers stated a 5% rate for new erectile dysfunction 
and 70-80% retrograde ejaculation rate, post-TURP.  
o Another clinical advisor recommended the 6-year follow-up on HoLEP by 
Gilling et al. (2008) for sexual function post-HoLEP; and a 76% retrograde 
ejaculation rate was reported, which is similar to that quoted by our clinical 
experts for TURP. IIEF improvement from baseline is not reported. 
 Catheterisation rates vary due to local procedures (e.g. some hospitals seem to 
catheterise post-procedurally as a matter of course) so this is a difficult comparison 
to make. Post-procedure catheterisation times were shorter for Urolift (22.3 hrs, no 
SDs reported) compared to TURP (62.7 hours ± 37.4) and HoLEP (44.2 hours ± 26.8). 
However, this again could be decided by local procedures rather than patient need, 
or a genuine difference between the surgical procedures. 
The mild complications of the Urolift procedure may be enough to for some patients, 
concerned about blood loss or TUR syndrome, to prefer Urolift if it was offered to them as 
an alternative to TURP and HoLEP by their urologist.  
3.10 Conclusions on the clinical evidence 
The sponsor’s submission uses pooled effect sizes to show mean changes from baseline in a 
number of key areas: prostate symptom score measures (IPSS, BPHII), health-related quality 
of life (IPSS QoL), male sexual health (IIEF, MSHQ-EjD, MSHQ-Bother) and urological function 
(Qmax and PVR) up to 12-months post-Urolift. The presented meta-analysis indicates a large 
improvement in prostate symptom scores and QoL, a small improvement (but not negative 
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impact) on sexual health. The authors note that Qmax and PVR were inconsistently reported, 
leading to a higher heterogeneity score in their meta-analysis, which made true effects 
difficult to assess.  
The EAC considers that this meta-analysis does show that Urolift is clinically effective, but is 
not a clear representation of the data. The methodology in the systematic review paper was 
short and lacked transparency, certain patients from some of the publications could have 
been double-counted (multiple publications covered some of the cohorts involved, but 
again, this is not clearly stated in the methods) and effect sizes are less clear than simply 
using the units of the outcome measures themselves. The EAC attempted to address this in 
our analysis by maintaining the original units of the outcome measures of each study, rather 
than converting to effect sizes, and taking a more simplified approach of reporting the mean 
change from baseline in each outcome measure reported.  
Overall, the studies used in the sponsor’s submission show that Urolift is a clinically effective 
device for the treatment of BPH. However, this relies upon context. Using the IPSS score as a 
primary outcome for symptom improvement, the published minimally important change in 
IPSS score is 3 (Barry et al. 2005), and Urolift delivers a weighted mean IPSS improvement of 
between 9.22 – 11.82 points. These Urolift improvements are also larger than the published 
“marked improvement” in IPSS score of 8.8 (Barry et al. 1995). Therefore, in light of the 
published evidence on the IPSS tool, Urolift delivers very satisfactory clinical results. 
However, the EAC comparison using papers selected by a recent TURP vs. HoLEP systematic 
review (Li et al. 2014) showed that patients with a similar range of baselines (age, IPSS 
score, prostate volume, Qmax) made much better improvements in IPSS with both TURP and 
HoLEP. A similar effect is seen in IPSS QoL, Qmax, and PVR: although improvements are made 
with Urolift, all symptom-related measures improve more dramatically with both TURP and 
HoLEP. 
Sexual function is poorly reported in the TURP and HoLEP RCTs (the study aims are mostly 
based around symptom improvement, so sexual function impact is secondary outcome, and 
a complication), and therefore it is difficult to ascertain the impact of these interventions on 
erectile and ejaculatory function. The evidence shows that Urolift does not negatively affect 
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these outcomes, but small improvements are achieved, however these are not always 
statistically significant. 
The mild complications of the Urolift procedure (mainly dysuria and haematuria) may be of 
interest to some patients, specifically those wishing to avoid blood loss or TUR syndrome. 
These were either not reported as a complication of Urolift, or are not possible with Urolift, 
respectively. Furthermore, the clinical improvements of IPSS (discussed above) may also be 
enough to satisfy patients with severe BPH, as a 10 point improvement would carry a 
patient from “severe BPH” (20-35 points) to “moderate BPH” (8-19 points) (British 
Association of Urological Surgeons). 
Therefore, the evidence may support Urolift being used an  alternative, based upon patient 
preference, for symptom relief lower than that of TURP or HoLEP, but at reduced risk of the 
more dangerous complications. 
 Table 33 Overview of outcome measures 
 
Published or clinical expert 
opinion – minimally important 
change 
Urolift TURP HoLEP 
IPSS 
(Negative score is 
improvement) 
Minimum = 3.0 
Moderate = 5.1 
Marked change = 8.8 
(Barry et al. 1995) 
1 month -10.35 
3 month -11.82 
12 month -10.49 
24 month -9.22 
1 month -17.34 
3 month  -19.70 
12 month  -18.13 
24 month -17.50 
1 month -17.68 
3 month  -20.88 
12 month  -19.29 
24 month -20.40 
IPSS QoL 
(Negative score is 
improvement) 
  
Minimum = 1-3 
(Clinical expert opinion) 
1 month -2.27 
3 month -2.48 
12 month -2.31 
24 month -2.22 
1 month -2.99 
3 month  -2.80 
12 month  -3.18 
24 month N/A 
1 month -2.64 
3 month  -3.00 
12 month  -3.24 
24 month N/A 
BPHII 
(Negative score is 
improvement) 
Minimum = 0.5 Moderate = 1.1 
Marked changed = 2.2 
(Barry et al. 1995) 
 1 month -3.29 
3 month -3.96 
12 month -3.95 
24 month -3.76 
N/A N/A 
IIEF 
(Positive score is 
improvement) 
 
Minimum = 4 
(Clinical expert opinion) 
1 month +0.52 
3 month +1.34 
12 month +0.80 
24 month N/A 
N/A N/A 
MSHQ-EjD 
(Negative score is 
improvement) 
 
Minimum = 1.5 
(Clinical expert opinion) 
1 month +1.82 
3 month +1.47 
12 month +0.83 
24 month N/A 
N/A N/A 
MSHQ-Bother 
(Negative score is 
improvement) 
 
Minimum = 1.0 
(Clinical expert opinion) 
1 month -0.67 
3 month -0.79 
12 month -0.91 
24 month N/A 
N/A N/A 
Qmax (ml/s) 
(Positive is improvement) 
 
Minimum = 2ml/s 
(NICE CG97) 
1 month +4.16 
3 month +3.78 
12 month +3.52 
24 month +4.15 
1 month +14.58 
3 month  +14.11 
12 month  +16.69 
24 month +23.20 
1 month +15.29  
3 month  +18.25 
12 month  +17.78 
24 month +23.10 
PVR (ml) 
(Negative is improvement) 
 
Minimum = 50 ml 
 (Clinical expert opinion) 
1 month -7.00 
3 month -10.34 
12 month -5.72 
24 month N/A 
1 month -137.43 
3 month  -89.34 
12 month  -127.29 
24 month -196.10 
1 month -160.23 
3 month  -78.00 
12 month  -161.47 
24 month -231.40 
 4 Economic evidence 
4.1 Published economic evidence 
4.1.1 Critique of the sponsor’s search strategy 
The sponsor has combined the search for relevant economic studies with a search for 
evidence to inform model inputs. Therefore the search is broader than the PICO in the 
scope, for example including studies that evaluate interventions/procedures other than 
Urolift. The search terms used were: 
(Benign prostatic hyperplasia OR benign prostatic enlargement) AND Cost 
The use of ‘AND cost’ is overly restrictive, since some studies may include other terms such 
as economic, or variations on this. The clinical terms are also restrictive and more terms 
should have been included, such as LUTS and variations on this. 
NHS EED was searched for economic evidence. The NHS EED database is populated by a 
search of CINAHL, Embase, MEDLINE, PsycINFO and  PubMed, which already incorporates an 
economic filter, therefore there was no need to include ‘AND cost’. If possible a search of 
EconLit would have made the search for evidence more thorough. The sponsor’s submission 
also included a search of the manufacturer’s internal literature databases and reference list 
checking of all relevant study publications. The search for evidence did not include citation 
tracking of included studies or contacting authors of the included studies 
Grey literature was searched using Google and there was a search of the NICE website. 
The EAC conducted a search in the following databases: Cost Effectiveness Analysis; EcoLit; 
HEED and  NHS EED for economic evidence concerning Urolift. This was in addition to the 
searches for clinical evidence described in 3.1, which would have also identified economic 
evidence. The EAC search identified 40 citations. 
4.1.2 Critique of the sponsors study selection 
The sponsor provided a flow chart to describe the study selection process. Studies were 
excluded if they: 
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 Did not take a UK perspective 
 Did not look solely at BPH 
 Were focused on specific sub-groups 
 Evaluated non-BPH treatments 
4.1.2 Included and excluded studies 
None of the studies included by the sponsor included Urolift. They were all economic 
studies of the comparators, including comparators in the scope and others outside the 
scope. Therefore none of the studies are appropriate for inclusion, although some may 
include useful data for inputs to the model regarding the comparators. 
The EAC conducted a thorough search for economic studies relevant to the scope, described 
in 4.1. No relevant economic studies were identified. 
4.1.3 Overview of methodologies of all included economic studies 
N/A 
4.1.4 Overview and critique of the sponsor’s critical appraisal for each study 
The sponsor carried out a critical appraisal for each economic study, but as these were not 
relevant to the scope, this was not required. 
4.1.5 Does the sponsor’s review of economic evidence draw conclusions from the data 
available?  
The sponsor noted that ‘no cost-effectiveness analysis comparing these technologies in the 
NHS is currently available’ and this is the rationale for the de novo model. 
4.2 De novo cost analysis 
Patients 
The population considered in the model is men with LUTS secondary to BPH aged ≥ 50 
years, and with prostate volume no greater than 100cc. This accords with the population in 
the scope. 
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Technology 
The technology in the model is Urolift, in accordance with the scope. The results for Urolift 
are presented alongside the comparators. 
Comparator(s) 
In the model the sponsor included TURP and HOLEP as comparators in agreement with the 
scope. The executable model also included Bipolar TURP, laser vapourisation (e.g. KTP laser) 
TUVP, and Bipolar TUVP as comparator arms but in the sponsor submission only the 
comparators in the scope are presented. 
Model structure 
The model structure is a decision tree, with seven executable arms, one for each technology 
or comparator. Following treatment the outcomes are success or failure. The success 
category then has options for relapse or no relapse. The relapse option then has success or 
failure outcomes. The failure outcome has options for re-treatment (with success or failure 
outcomes) or no re-treatment. 
Figure 2 Flow diagram of sponsor’s de novo economic model 
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There are three possible perspectives to be selected in the executable model: 
1. Hospital (1 year timeframe) 
2. Primary Care Trust (1 year timeframe) 
3. National (NHS) 2 year time horizon 
The sponsor submission refers only to the NHS perspective and 2 year time horizon. The two 
year time horizon was chosen to be long enough to assess the majority of differences in 
outcomes, treatment related adverse events and re-interventions. It is also the maximum 
length of follow-up available in the published evidence for Urolift. 
The overall structure of the model is cumbersome because of the inclusion of comparators 
outside the scope, pre-operative and post-operative tests which are the same regardless of 
the intervention and options for additional perspectives not referred to in the submission. 
The model includes detailed costing for complications. For example, incontinence includes the costs 
of drugs, incontinence bags and pads and nurse visits. The costs are taken from reliable sources.  
Model assumptions 
The sponsor provided a comprehensive list of 21 assumptions in the model together with a 
justification for each. The list is reproduced below in Table 35, together with EAC comments. 
Table 34 Model assumptions 
Assumption Justification EAC comment 
The initial procedure is either successful 
or not. Failure is defined as failure to 
achieve ≥10% improvement in IPSS 
score relative to baseline within 30 days 
of procedure 
In clinical practice a percentage change of 
less than 10% in IPSS is most often used 
to define insufficient improvement 
(Lourenco 2008) 
Accept 
In the base case, the proportion of 
patients who decide to undergo 
retreatment is the same for patients 
who have failed the initial treatment, 
and patients who had an initially 
successful procedure but then 
experience relapse 
 
Accept 
The mean IPSS score post treatment of 
patients who have failed is the same as 
the mean IPSS score pre-treatment, i.e. 
there is no change in mean IPSS score 
for failed patients: 
 
Accept 
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The probability of retreatment after 
failure is equal to the probability of 
retreatment after relapse. I.e. patients 
with an unsatisfactory treatment result 
after the initial procedure have the 
same probability of retreatment 
regardless of the reason (initial failure, 
or subsequent relapse after a 
successful result) 
 
Accept 
The success rate for subsequent 
procedures is lower than for primary 
procedures. The relative success of a 
subsequent procedure compared to a 
primary procedure is assumed to be 
0.75. 
This value was used in the model was 
estimated from clinical expert opinion 
(Lourenco 2008). 
Accept. Agrees with NICE CG97. 
In the base case, retreatment  is carried 
out using TURP for all patients except 
for those who have HoLEP as the initial 
procedure, for whom there is no 
surgical option 
TURP represents the 'gold standard' of 
surgical treatments for BPH.  Patients 
who have undergone a HoLEP procedure 
would not be eligible for further surgical 
treatment due to the enucleation of tissue 
in the prostate. 
Accept 
The operation time for UroLift is 
assumed to be 30 minutes 
Assumption based on clinical expert 
opinion 
Based on weighted mean in studies, 
EAC considers 60 minutes is the 
best available published data. This 
should be explored in sensitivity 
analysis. 
The operation time for TURP is 
assumed to be 60 minutes 
Assumption based on clinical expert 
opinion 
Weighted mean of published studies 
is 66 minutes. 
The operation time for HoLEP  is 
assumed to be 76.96 minutes 
Calculated as the summation of operating 
time by TURP and the weighted mean 
difference obtained from a meta-analysis 
(Lourenco 2008) 
77 minutes is used in the sponsor’s 
model 
The operation time for  HoLEP  is 
assumed to be 58.38 minutes 
Calculated as the summation of operating 
time by TURP and the weighted mean 
difference obtained from a meta-analysis 
(Lourenco 2008) 
I think this refers to KTP laser rather 
than HoLEP 
Length of hospital stay = 0.5 days for 
UroLift 
Assumption based on clinical expert 
opinion 
EAC clinical experts consider Urolift 
to be a day case procedure. 
Length of hospital stay = 3.03 days  for 
TURP 
Weighted average of HRG4 codes 
LB25A, LB25B, LB25C (HSCIC 2013) 
EAC weighted mean = 5.08 days 
However this includes a study with 
unusually high number of TUR 
syndrome cases. Accept sponsor 
value. 
Length of hospital stay = 1.98 days  for 
HoLEP 
Calculated as the summation of operating 
time by TURP and the weighted mean 
difference obtained from the meta-
analysis (Lourenco 2008) 
EAC weighted mean = 4.08 days. 
However this includes one study with 
an unusually long LOS. Accept 
sponsor value. 
Length of hospital stay = 2.33 days  for 
Bipolar TURP 
Calculated as the summation of operating 
time by TURP and the weighted mean 
difference obtained from the meta-
analysis ((Lourenco 2008) 
Accept 
The total capital costs of equipment for 
TURP = 0.  
It was assumed that equipment for TURP 
is already available in the NHS 
EAC includes a capital cost of £10 
per patient for TURP equipment 
No. of cystoscopy sets used per 
procedure =1 
Clinical expert opinion 
Accept 
The number of pre- and post-operative 
tests and healthcare visits does not 
differ between any of the surgical 
interventions 
Clinical expert opinion 
Agree but the sponsor claimed 
‘significantly lower number of post 
discharge follow-on visits’ for Urolift. 
One clinical expert agreed that 
complications were lower with Urolift 
than TURP/HoLEP so fewer post-
procedure visits needed. One clinical 
expert stated that more post-
procedure visits were needed in the 
short term because Urolift is new 
and lacks data. 
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Each treatment is associated with the 
same levels of operating staff (1 
consultant surgeon, Consultant 
anaesthetist, 1 band 5 nurse and 1 
healthcare assistant  
Clinical expert opinion 
Clinical advisers suggested an 
additional laser operator is needed 
for HoLEP. 
For all procedures excluding UroLift, 
there is risk of permanent incontinence 
The risk of incontinence from each 
procedure were derived from the 
identified from meta-analyses (Lourenco 
2008).  For UroLift no cases of permanent 
incontinence post-procedure have been 
reported for any patient receiving the 
procedure to date. Clinicians also 
indicated that the procedure was very 
safe and had no effect on incontinence  
Accept 
Mortality is excluded from the model There is no evidence to suggest that 
treatments for BPH influence overall 
survival. Hence, due to the short time 
horizon of the model, mortality was 
excluded from the model. 
Agree 
Costs were discounted at 3.5% This is the rate recommended by NICE 
technology evaluation programme (NICE 
2011) 
Agree 
The EAC did not identify any additional model assumptions. 
Clinical parameters and variables 
Data sources used for clinical parameters for Urolift were the papers by Lourenco 2008, 
Chin 2012 and Woo 2011 and unpublished data from Roehrborn 2014. 
Table 35 Probability of success per procedure (>10% improvement in IPSS within 12 months) 
UroLift TURP HoLEP Bi-TURP 
89.08% 94.00% 96.71% 94.00% 
 
Table 36 Probability of relapse after successful procedure (long term) 
UroLift TURP HoLEP Bi-TURP 
0.00% 0.17% 0.32% 0.99% 
The probability of relapse for Urolift after successful procedure (long term) is based on 
limited data since only one study extended to 2 years and all other studies stopped at 12 
months post procedure. Therefore it is difficult to be confident that there is zero chance of 
relapse. The EAC has looked at the effect of increasing the probability to 0.2% on the results 
of the model, and this increases the cost of Urolift by £4. 
Table 37 Probability of re-treatment within 31 days (short term) 
UroLift TURP HoLEP Bi-TURP 
0.75% 0.31% 0.21% 0.45% 
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Table 38 Probability of adverse effects per procedure (%) 
 UroLift TURP HoLEP Bi-TURP 
Incontinence 0.00% 3.00% 2.91% 1.77% 
Urinary retention 5.71% 5.00% 3.55% 8.55% 
UTI 1.40% 6.00% 5.88% 6.00% 
Stricture 0.00% 7.00% 5.88% 9.66% 
TUR syndrome 0.00% 3.00% 0.93% 3.00% 
Decrease in erectile function 0.00% 9.15% 9.06% 9.15% 
Increase in erectile function 0.00% 3.42% 4.32% 3.42% 
Ejaculation dysfunction 0.00% 37.45% 33.44% 37.45% 
 The EAC found the weighted mean for incontinence to be 5% (CI 3% to 8%), but this 
included stress and urgency incontinence. No permanent incontinence was reported for 
Urolift, therefore the EAC accepts the sponsor value.  
The EAC calculates UTIs as 5% (CI 3% to 7%) for Urolift from the published studies, which is 
actually higher than claimed and similar to comparators. Considering that the operation 
time is similar, sterility of components is the same; we might expect similar UTI rates. 
Perhaps the lack of irrigation in Urolift could reduce the UTI rate. 
The model doesn’t specifically include:  
  3% (CI 1% to 10%) prostatitis 
  3% (CI 1% to 6%) orchitis/epididymitis 
It is possible that these are included in UTI in the model, but these are not clearly reported 
in the published literature. 
The EAC considered the erectile and ejaculatory function for Urolift is fine at 0%. There was 
actually a small mean improvement in IIEF (although not statistically significant), for 
example. 
Procedural variables in the model including hospital LOS (0.5 days) and procedure time (30 
minutes) for Urolift were based on clinical opinion of three experts. Procedure time was 
quite well reported in the literature, and the EAC calculated weighted mean was 59.6 
minutes. One paper (Abad 2013) reported a 19 minute procedure time under general 
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anaesthetic, but this was a small study and all of the other studies showed close agreement 
for a procedure time with a range from 52-66 minutes. 
 None of the studies reported LOS for Urolift, therefore it is reasonable to use expert 
opinion to inform the base case. However, the sensitivity analysis needs to be across a 
broad range of values as there is considerable uncertainty around this estimate. LOS could 
be longer than 0.5 days, particularly since patients are reported to be catheterised for a 
weighted mean of 22.3 hours (this assumes that patients were not sent home with 
catheters in situ).  
The EAC consulted clinical experts regarding LOS and operative time for Urolift. The 
responses were varied, but the majority classed Urolift as a true day case procedure. One 
adviser commented that the operative time in the published literature (59.6 minutes) may 
reflect trial conditions and that practical experience confirmed a 30 minute procedure time 
was normal. 
Resource identification, measurement and valuation 
The number of Urolift devices is a key driver of the model and in the base case the sponsor 
has used 4 as the number of devices per procedure. The reference given for this value is 
Chin 2012 and in the executable model it states this was also validated by clinical experts. 
The EAC agrees that Chin 2012 reported the mean number of devices per procedure to be 4, 
but published studies reported using between 2 and 9 devices per procedure. The EAC 
calculated the weighted mean number of implants from all of the clinical studies and found 
this to be 4.4 devices per procedure. We suggest that this is a more representative value for 
this parameter.  
The cost of blood transfusion has been overestimated by the sponsor as £862.17 per 
transfusion. The data source (NICE CG97) references Varney and Guest (2003) and in this 
paper the authors conducted a top down cost analysis of transfusion services. It was 
assumed that a transfusion would increase LOS by 1 day and this was included in the cost of 
transfusion (£635 in 2003 inflated by the sponsor to current value of £826.17). The LOS for 
the comparators in the model is based on data from Lourenco (2008) and would include any 
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increase in LOS for blood transfusion. Therefore the sponsor is double counting 1 extra day 
LOS for patients having blood transfusion. The EAC estimates the cost of blood transfusion 
as £329. 1 unit standard red cells = £ 121.85 (NHS Blood and Transplant price list 2014/15. 
The mean number of units per transfusion is estimated to be 2.7 units of red blood cells 
(Varney and Guest 2003). Therefore the EAC calculates 2.7 x £121.85 = £329 per transfusion. 
Although blood transfusion only occurs in 8% of patients undergoing TURP and fewer 
patients having HoLEP procedure (relative risk for HoLEP compared with TURP = 0.27), the 
probability of blood transfusion for Urolift in the model is 0, therefore this change reduces 
the cost of the comparators, but not Urolift.  
The unit cost of hospital stay has been taken from published Scottish data for Urology 
specialty in-patient costs, divided by the average length of stay (3.3 days) to give the unit 
cost per day in hospital. The excess bed day cost used in the model is calculated from the 
HRG code for TURP, minus the procedure costs included in the model. It is not very clear 
which procedure costs have been subtracted. The result is £331 in 2012 prices which is 
inflated to £344 current price. The cost used in the model for hospital stay (0.5 days) for 
Urolift is calculated from 0.5 x £344 = £172. For comparison the EAC found the cost of an 
excess bed-day from the National Schedule of reference costs 2013-14 to be £294 (Excess 
bed day LB25F).  
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Technology and comparators’ costs 
The list price of Urolift implants is given as £330 excluding VAT per device by the sponsor. 
Table 39 Consumables included in the sponsor's model 
 Details Cost per 
procedure 
EAC comment 
Urolift 4 implants @ £330 £1320 This is the largest component in 
the cost of Urolift. 
mTURP 1 loop electrode @ £52.50 £52.50 Assume use of 1 loop electrode 
& 1 roller/ball in 100% of cases. 
Based upon NHS Supply Chain 
list of diathermy equipment 
costs: 
Covidien E7506 Diathermy plate 
standard (solid) with 
leadwire =  £4.04 
Loop electrode (models suitable 
for mTURP =  £26.40 
Roller/ball electrode (models 
suitable for mTURP =  £26.40 
Total   =   £56.84 
HoLEP Reusable fibre @ £614.37 (20 uses) 
Reusable morcellator @ £664.63 (10 
uses) 
£97.18 EAC investigated single use fibre 
@ £368.61 from NHS supply 
chain 
Bi-TURP 1 loop electrode @ £52.50 £52.50 Change to £56.84 as above 
The sponsor includes in the model the option to not re-use the HoLEP consumables, but 
there is no adjustment in the price of these. Selecting this option increases the cost of 
HoLEP from £1924 per procedure to £3106, making Urolift cost saving compared with 
HoLEP. The EAC considers that single use consumables would be offered at a lower price 
than multi-use consumables. It is unlikely that hospitals would dispose of multi-use 
consumables after a single use, so we consider this option unrealistic. The EAC looked at the 
result of using single use laser fibres @ £368.61 from NHS supply chain catalogue price, but 
we retained the re-usable morcellator blade as we did not find a cost for these from NHS 
supply chain or a manufacturer. 
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Table 40 Capital costs of equipment used in the sponsor's model 
 
Capital cost (assumed lifespan of equipment of 10 
years, and used for 250 patients/year) 
Cost per 
procedure 
Urolift £5199 £2.50 
mTURP £0 £0 
HoLEP £167,555 £80.60 
Bi-TURP £0 £0 
There is an option in the model to replace the purchase of the capital equipment with a 
contract for a number of consumables over a time period. If this option is selected for 
Urolift the capital cost of the equipment (£5199) is excluded from the model. However 
nothing else changes in the model, so selecting this option for Urolift has the effect of 
simply subtracting £2.50 from the cost per patient of the procedure. Therefore it has 
minimal effect on the outcome of the model. For HoLEP where the capital equipment costs 
are significant (£167,555), choosing this option has the effect of reducing the cost of HoLEP 
from £1924 to £1843 per patient, the difference being £81, which is the cost per procedure 
of the capital equipment. The EAC considers it likely that manufacturers would charge a 
higher price per consumable item if such a contract were agreed in order to recoup the 
capital cost of the equipment. The EAC consulted clinical advisers about this, but we were 
unable to obtain specific details of negotiated contracts, which may vary between 
manufacturers and NHS organisations. 
Sensitivity analysis 
Since the base case shows Urolift to be more costly than the comparators, sensitivity 
analysis is of great importance. The sponsor has identified the key drivers in the model 
based on the sensitivity analysis. For Urolift the model is driven by the cost of the device 
and the number of devices used for each patient.  
The results of sensitivity analysis were not saved in the executable version of the model, so 
it was necessary to change each parameter in turn, run the model and record the results. 
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For parameters investigated in sensitivity analysis the upper and lower values used were 
±20% of base case values. This is reasonable when the variable is known with some 
certainty, but where the parameter is based on opinion of a small number of clinicians or on 
poor quality data, it would be more robust to allow the parameters to take a wider range. 
Hospital length of stay was not identified as a key driver for Urolift in the model, but as 
there was no published data on LOS for Urolift, the sponsor relied on clinical opinion (3 
clinicians) for the estimate of 0.5 days. Sensitivity analysis considered this variable, and it 
was varied by ±20%, so the range considered was 0.4 days to 0.6 days.  
For the length of operation, which is estimated to be 30 minutes for Urolift it would be 
helpful to see a more robust sensitivity analysis, rather than a standard ±20% variation.  
In the sensitivity analysis the sponsor has assumed in the base case that the HoLEP 
consumables (laser fibre and morcellator) are re-used 20 and 10 times respectively. An 
additional scenario was analysed in which reuse of HoLEP consumables was not permitted. 
The EAC found that NHS supply chain offer both single use and reusable laser fibres for 
HoLEP, and the reusable fibres are more expensive. For example Cook Medical multi-use 
fibres cost £1207.42 each, but their single use fibres cost £368.61. The sponsor has used the 
same price for single use and multi-use fibres and morcellators. Based on the source of the 
data these appear to be multi-use fibres. The sponsor appears to suggest that hospitals are 
disposing of multi-use consumables after a single use and the EAC considers this to be an 
unlikely scenario.  
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4.3 Results of de novo cost analysis 
Base-case analysis results 
The sponsor’s base case results are shown in Table 9.2.5 taken from the sponsor’s 
submission and this matches the results in the executable model. The sponsor also 
presented the incremental costs for Urolift (Table 9.2.6 in the sponsor’s submission) . The 
EAC has combined these tables below, in T able 41. 
Table 41 Sponsor's base case results 
Intervention Total cost per patient  Incremental cost of Urolift 
UroLift £2 342 - 
TURP £2 339 +£3 
HoLEP £1 924 +£ 418 
Bipolar TURP £2 302 +£40 
 
The threshold at which Urolift becomes cost neutral compared with mTURP is reached when 
each Urolift device falls in price from £330 to £329. The sponsor also included a breakdown 
of costs by category reproduced below in Table 27. It is evident from this table that Urolift 
has much greater equipment costs per procedure than the comparators, but lower clinical 
supplies and services costs due to the estimated shorter length of hospital stay. 
Table 42 Sponsor's breakdown of costs 
Item UroLift TURP HoLEP Bi-TURP 
Medical 
1
 £342 £423 £457 £410 
Nursing £64 £113 £137 £105 
Drugs
2
 £22 £21 £20 £21 
Clinical supplies and services 
3
 £549 £1,358 £923 £1,222 
Equipment cost per procedure £1,325 £56 £97 £56 
Other
4
 £40 £369 £290 £487 
TOTAL £2,342 £2,339 £1,924 £2,302 
1Consultant staff costs, 2Cost of anaesthetic doses, saline, and antibiotics, 3Includes cost of tests pre- and post- procedure 
and hospital bed day costs, 4Includes costs of complications and capital costs 
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Sensitivity analysis results 
The results of sensitivity analysis are not presented very clearly by the sponsor and so the 
EAC has calculated the results of sensitivity analysis undertaken by the sponsor and these 
are presented in Table 43 below. 
Table 43 Results of sponsor's sensitivity analysis 
Parameter   UroLift TURP HoLEP Bi-TURP 
Base case   £2342 £2339 £1924 £2302 
UroLift device cost 
per procedure 
+20% £2606    
-20% £2078    
12 month failure 
probability 
+20% £2389 £2362 £1926 £2322 
-20% £2295 £2319 £1922 £2282 
Duration of operation 
+20% £2373 £2404 £2003 £2359 
-20% £2311 £2274 £1845 £2239 
Length of stay 
+20% £2376 £2560 £2061 £2432 
-20% £2308 £2120 £1786 £2044 
 
Other parameters tested in sensitivity analysis are listed in Table 44 below. These had a 
uniformly small impact on the model (less than 1%) for all procedures. 
Table 44 Other parameters tested in the sponsor's sensitivity analysis 
Probability of incontinence after TURP 
Probability of blood transfusion after TURP 
Probability of urinary retention 
Probability of UTI 
Probability of stricture 
Probability of TUR syndrome after TURP 
 
Subgroup analysis 
No subgroup analysis was undertaken by the sponsor. A sub-group of interest identified in 
the scope was ‘Men for whom TURP or HoLEP is unsuitable because of difficulties with 
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blood loss or sedation’.  No evidence was found for this sub-group on which to base a model 
scenario. 
Model validation 
The sponsor states that the model was subject to internal quality checking. No published 
studies comparing Urolift with TURP or HoLEP were found, therefore the model could not 
be validated against any published results. The sponsor noted that in respect of the 
comparators, the results were consistent with published models, showing HoLEP is less 
costly than TURP. 
4.4 Interpretation of economic evidence 
The sponsor cites the lack of comparative efficacy data between Urolift and TURP or HoLEP 
as a weakness of the submission. The sponsor identifies a resource saving of 27 minutes of 
operating room time. In the model the reduction in operating time only included a 
reduction in staff time. There was no cost of the operating theatre included. The EAC have 
accounted for this in section 4.5, Table 48 Effect of adding theatre overhead costs to the 
sponsor's model. 
4.5 Additional work undertaken by the External Assessment Centre in 
relation to economic evidence 
The EAC sought to verify the sponsor’s estimate for length of hospital stay for Urolift 
patients with clinical advisers. There was some variation in the responses, but all confirmed 
that the Urolift procedure can be considered day case, and that length of stay would be 
measured in hours rather than days. All EAC changes to the model were also accompanied 
by threshold analysis, where the cost per Urolift implant could be altered to allow Urolift to 
become cost neutral compared to mTURP. 
Based on the weighted mean of studies reporting the number of Urolift implants used per 
procedure, the EAC substituted the sponsor’s estimate of 4 with the weighted mean of 4.4. 
This had the effect of increasing the cost of Urolift by £132. The threshold analysis at which 
Urolift achieves cost neutrality with mTURP under these conditions is £299 per implant.  
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Table 45 Effect of changing the number of Urolift implants 
Model input  Values Urolift mTURP HoLEP BiTURP 
No of Urolift 
implants 
Sponsor 4 £2342 £2339 £1924 £2302 
EAC 4.4 £2474 £2339 £1924 £2302 
 
The EAC changed the sponsor’s estimate of 30 minutes for the operation time for Urolift to 
60 minutes based on the weighted mean of reported operation time from published studies. 
This had the effect of increasing the cost of Urolift by £154. The threshold analysis at which 
Urolift achieves cost neutrality with TURP under these conditions is £291 per implant. 
Table 46 Effect of changing the procedure time for Urolift 
Model 
input 
 Values Urolift mTURP HoLEP BiTURP 
Operation 
time for 
Urolift 
Sponsor 30 minutes £2342 £2339 £1924 £2302 
EAC 60 minutes £2496 £2339 £1924 £2302 
The EAC changed the mTURP procedure time from the sponsor’s 60 minutes to the 
weighted mean of 66 minutes taken from the EAC comparator studies. This increased the 
cost of mTURP so that Urolift became cost saving, by £26 per patient. Threshold analysis 
shows that Urolift implants would cost £337 each in order to make them cost neutral with 
mTURP. 
 Table 47 Effect of changing the procedure time for mTURP 
Model 
input 
 Values Urolift mTURP HoLEP BiTURP 
Operation 
time for 
mTURP 
Sponsor 60 minutes £2342 £2339 £1924 £2302 
EAC 66 minutes £2345 £2371 £1924 £2302 
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The sponsor claims that Urolift can save 27 minutes of operating theatre time, but the EAC 
could not find operating theatre time cost accounted for in the model. We took the cost of a 
urology operating theatre from NICE CG97, stated at £9 per minute. For an hour’s operation 
this is £540. We inflated this to 2015 values and then subtracted the staff costs from the 
sponsor’s model, leaving an operating theatre overhead cost of £314 (£5.23 per minute). 
We validated this by comparison with another economic analysis by Noble et al. (2002), who 
give an inflation-adjusted cost for urological theatre time of £280 per hour (separate from 
staff costs). There is nowhere in the model to include theatre overheads, but we used £314 
per hour as a theatre overhead cost, and inserted £5.23 per minute into the line titled “Band 
5 nurse (second)” in the sponsor’s economic model. This gives a per-minute cost to account 
for the theatre time in the model. This produces a cost saving of £139 compared to mTURP 
and £79 compared to BiTURP. 
Table 48 Effect of adding theatre overhead costs to the sponsor's model 
Model 
input 
 Values 
Urolift (30 
mins) 
mTURP (60 
mins) 
HoLEP (76.96 
mins) 
BiTURP 
(55.44 mins) 
Theatre 
overheads  
Sponsor £0 £2342 £2339 £1924 £2302 
EAC 
£5.23 per 
minute 
£2532 £2671 £2372 £2611 
 
Some clinical experts advised that TURP may need an extra band 5 nurse over Urolift to 
handle irrigation fluid, so the EAC changed this. This was done for mTURP and BiTURP. 
These staffing changes made Urolift cost saving over mTURP, by £78, and BiTURP by £34.   
Table 49 Effect of adding an additional band 5 nurse to mTURP and BiTURP 
Model 
input 
 Values Urolift mTURP HoLEP BiTURP 
Band 5 
nurse 
Sponsor 
1 band 5 
nurse 
£2342 £2339 £1924 £2302 
EAC 
2 band 5 
nurses 
£2351 £2429 £1924 £2385 
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The EAC changed the cost of blood transfusion in the model from £862.17 which includes 
double counting of 1 additional day in hospital to the EAC estimate of £329. This had the 
effect of reducing the cost of the comparators such that Urolift costs £44 more than mTURP, 
compared with £3 more in the base case. Threshold analysis shows that under these new 
conditions, Urolift implants would have to be priced at £319 per implant to achieve cost 
neutrality with mTURP. 
Table 50 Effect of changing the blood transfusion cost 
Model input  Values Urolift mTURP HoLEP BiTURP 
Cost of 
transfusion 
Sponsor £862.17 £2342 £2339 £1924 £2302 
EAC £329 £2338 £2294 £1913 £2255 
The EAC included a £10 per procedure cost for capital equipment for TURP (total capital cost 
£20,799 used both mTURP and biTURP) as the sponsor did not include the capital cost in the 
base case. This had the effect of increasing the cost of the TURP comparators such that 
Urolift became cost saving compared with mTURP by £7 per patient.  
Table 51 Effect of including the capital equipment costs for TURP 
Model input  Values Urolift mTURP HoLEP BiTURP 
Cost of 
mTURP  and 
BiTURP 
capital 
equipment 
Sponsor £0 £2342 £2339 £1924 £2302 
EAC £10 £2343 £2349 £1924 £2312 
 
mTURP procedures use a roller or ball electrode in addition to the loop electrode in up to 
100% of cases. mTURP also requires a return electrode plate. The EAC found costs for these 
electrodes from NHS supply chain catalogue. Our total consumables cost for mTURP comes 
to £56.84, which is slightly higher than the cost used by the sponsor. The effect on the 
model is to make Urolift cost neutral compared to mTURP. This was also done for BiTURP 
consumables, but did not make Urolift cost saving when compared to BiTURP 
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Table 52 Effect of changing the cost of mTURP and BiTURP consumables 
Model input  Values Urolift mTURP HoLEP BiTURP 
Cost of 
mTURP  
consumables 
Sponsor £52.50 £2342 £2339 £1924 £2302 
EAC £56.84 £2343 £2343 £1924 £2306 
 
The HoLEP fibres are priced differently when they are single-use. In light of this, the EAC 
took a price of £368.61 for single-use HoLEP fibres from NHS Supply Chain, and limited them 
to single use in the sponsor’s model. Under these conditions, Urolift was still cost incurring 
compared to HoLEP, by £80 per patient. 
.Note: The EAC were unable to find a cost for single-use morcellator blades (either through 
Supply Chain or by contacting a manufacturer, Lumenis (Versacut)) and this means they may 
not be available or widely used. Therefore, we retained the sponsor’s original figures for re-
useable morcellator blades. 
Table 53 Effect of changing the HoLEP fibres to single-use 
Model 
input 
 Values Urolift mTURP HoLEP BiTURP 
HoLEP 
fibres 
Sponsor 
£614.27, 20 
uses 
£2342 £2339 £1924 £2302 
EAC 
£368.61, 
single use 
£2342 £2339 £2262 £2302 
 
Some clinical experts advised that HoLEP may need an extra band 5 nurse as a laser 
operator, so the EAC changed this. Urolift was still cost incurring compared to HoLEP under 
these conditions, by £309 per patient. Urolift becomes cost saving with this change when 
the price of the Urolift implants falls to £252 each. 
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Table 54 Effect of adding an additional band 5 nurse (laser operator) to HoLEP 
Model 
input 
 Values Urolift mTURP HoLEP BiTURP 
Band 5 
nurse 
Sponsor 
1 band 5 
nurse 
£2342 £2339 £1924 £2302 
EAC 
2 band 5 
nurses for 
HoLEP 
£2342 £2339 £2033 £2302 
When all EAC changes are incorporated in the model simultaneously, Urolift is cost incurring 
compared with all other options. 
Table 55 Effect of all EAC changes to the model 
Model input Urolift mTURP HoLEP BiTURP 
Base case £2342 £2339 £1924 £2302 
All EAC changes £2979 £2707 £2762 £2579 
Incremental cost of 
Urolift (negative if 
Urolift is cost 
saving) 
 £272 £217 £400 
Threshold analysis for all the EAC conditions shows that each Urolift implant would have to 
cost £268 in order to achieve cost neutrality with mTURP. 
There is remaining uncertainty in the LOS for Urolift which is based on clinical opinion. The 
EAC has contacted clinical advisers and there is consensus that Urolift is a truly day case 
procedure. The sponsor sensitivity analysis considered LOS in the range 0.4 to 0.6 days. The 
EAC considers this too narrow and looked at the range 0.25 to 1 days LOS. At 0.25 days, 
Urolift is cost saving against mTURP by £83, and threshold analysis gives a Urolift implant 
cost of £351 per implant. At 1 day’s LOS, Urolift is cost incurring compared to mTURP by 
£175, and threshold analysis shows that cost neutrality would require a cost of £286 per 
implant. 
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Table 56 EAC sensitivity analysis on LOS 
Model input  Urolift mTURP HoLEP BiTURP 
Base case LOS 0.5 days £2342 £2339 £1924 £2302 
Urolift LOS EAC 
sensitivity 
0.25 days £2256    
1 day £2514    
The cost of a bed-day used in the model is based on an in-patient stay. The definition of day 
surgery in the UK is that ‘the patient must be admitted and discharged on the same day, 
with day surgery as the intended management’. Several patients per day may be admitted 
to the same trolley space in a dedicated day unit, providing greater efficiency than can be 
achieved for a day case in a general ward (AAGBI Day Case and Short Stay Surgery Guideline 
2011). Therefore, the actual length of stay for Urolift procedures is of great importance in a 
dedicated day surgery unit. 
We were also able to perform sensitivity analysis for reusable HoLEP fibres, at a cost of 
£1207.42 (NHS Supply Chain). This was used as an upper-limit sensitivity analysis for this 
input. Table 57 below shows that even at this increased cost, the high number of uses for 
these fibres means that it makes very little impact on the cost of HoLEP. 
Table 57 EAC sensitivity analysis for reusable HoLEP fibres 
Model 
input 
 Values Urolift mTURP HoLEP BiTURP 
HoLEP 
fibres 
Sponsor 
£614.27, 20 
uses 
£2342 £2339 £1924 £2302 
EAC 
£1207.42,  20 
uses 
£2342 £2339 £1954 £2302 
 
The model includes an option via a drop-down list to select Urolift performed under local 
anaesthetic. However, when selected there is no change in the result of the model and the 
EAC determined that this element of the model is not functioning.  
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4.5.1 EAC scenario 
Based on responses from clinical advisers to EAC questions the EAC has identified an 
optimistic but realistic scenario in which Urolift is cost saving compared with mTURP. In our 
scenario, we see the Urolift procedure undertaken within a dedicated day surgery unit.  
Table 58 EAC scenario inputs and conditions 
Input Conditions Source/notes 
Length of stay 0.125 days (3 hrs) Clinical expert advice 
Urolift procedure time 30 mins 
Clinical expert 
advice/sponsor’s model 
Number of Urolift implants 4* Sponsor’s model 
Local anaesthetic used for 
Urolift procedure 
Remove consultant 
anaesthetist cost from model 
Clinical expert advice 
Theatre overhead cost 5.23 per minute  
Added to model as Nurse 
Band 5 (second) 
mTURP procedure time 66 mins 
EAC weighted mean from 
clinical section of this 
Assessment Report 
Cost of blood transfusion £329 
EAC figure (sponsor’s 
original input was too 
high) 
 
Table 59 EAC scenario cost results 
 Urolift mTURP HoLEP BiTURP 
Sponsor base case £2342 £2339 £1924 £2302 
EAC scenario £2355 £2691 £2315 £2564 
Incremental cost of Urolift (negative 
if Urolift is cost saving) 
 -£336 £40 -£209 
In the scenario, Urolift is cost saving by £336 compared with mTURP and by £209 compared 
with BiTURP. 
*if the EAC figure of 4.4 Urolift implants is used (which accounts for the range of implant 
numbers required, reported as 2-9 in the Urolift studies), Urolift is still cost saving compared 
to mTURP and BiTURP under these conditions. 
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4.6 Conclusions on the economic evidence 
The sponsor’s submission relies on a de novo cost model. The model is comprehensive and 
somewhat overly complex as it includes pre- and post-procedure elements that are the 
same for the intervention and all comparators. The executable model also includes 
comparators not in the scope. The model options produce scenarios that the EAC considers 
unrealistic, such as the option for removing the capital equipment costs, but not changing 
the cost of consumables. 
The major limitation of the model is that the base case shows that Urolift is not cost saving 
against any of the comparators, although it is close to cost neutral compared with mTURP 
(+£3). There are limited opportunities to improve this position because the cost per 
procedure for Urolift is strongly driven by the large cost per procedure of the implants. The 
costs of the comparators are strongly driven by LOS, which is well reported in the literature. 
The EAC has made changes to the model, some of which are in favour of Urolift, but the 
overall effect of EAC changes is to worsen the position of Urolift compared with mTURP and 
BiTURP.  
Remaining uncertainties concern the LOS for Urolift, which is 0.5 days in the base case and is 
based on clinical opinion. The sensitivity analysis only considers a narrow range from 0.4 
days to 0.6 days. The EAC has increased this range from 0.25 days to 1 day because of the 
uncertainty in the value. If the LOS were 0.25 days, the cost per procedure for Urolift 
changes from £2342 to £2256, and Urolift becomes cost saving against mTURP and BiTURP. 
If the LOS for Urolift is increased to 1 day, the cost per procedure for Urolift increases to 
£2514 per procedure and Urolift remains the most costly of the interventions and 
comparators. After consulting clinical advisers regarding the LOS for Urolift, the EAC devised 
a scenario for Urolift undertaken in a dedicated day surgery unit, which was cost saving for 
Urolift compared with mTURP, with a £336 compared with mTURP and by £209 compared 
with BiTURP. 
. 
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4.6.1 Impact on the cost difference between the technology and comparator of additional 
clinical and economic analyses undertaken by the External Assessment Centre 
The impact of the EAC changes on the results of the model are summarised in Table 39 
below. Shaded rows of the table are results when Urolift becomes cost saving. 
 
Table 60 Impact of EAC changes on the model 
 Urolift mTURP HoLEP BiTURP 
Sponsor base case £2342 £2339 £1924 £2302 
No of Urolift implants = 4.4 £2474 £2339 £1924 £2302 
Operation time for Urolift = 60 
minutes 
£2496 £2339 £1924 £2302 
Operation time for mTURP = 
66 minutes 
£2345 £2371 £1924 £2302 
Addition of urological theatre 
overhead costs 
£2532 £2671 £2372 £2611 
Cost of transfusion = £329 £2338 £2294 £1913 £2255 
Cost of mTURP and BiTURP 
capital equipment per patient 
= £10 
£2343 £2349 £1924 £2312 
Cost of TURP consumables = 
£56.84 
£2343 £2343 £1924 £2306 
HoLEP fibres single use @ 
£368.61 
£2342 £2339 £2262 £2302 
Additional band 5 nurse for 
HoLEP 
£2342 £2339 £2033 £2302 
All above changes £2979 £2707 £2762 £2579 
EAC scenario £2355 £2691 £2315 £2564 
 
If all EAC changes are incorporated in the model, Urolift becomes cost saving compared with 
mTURP when the price for each Urolift device falls to £268. 
Urolift becomes cost saving compared with mTURP in the following circumstances, 
accepting the sponsor model, and making any one of the following changes only: 
 Increasing the operation time for mTURP from 60 to 66 minutes 
 Including the capital cost of equipment for mTURP £10 per patient 
 Decreasing the LOS for Urolift from 0.5 days to 0.25 days 
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 One additional band 5 nurse for mTURP 
 Including operating theatre overheads 
 The cost of a Urolift implant decreases from £330 to below £329 
Urolift becomes cost saving compared with BiTURP in the following circumstances, 
accepting the sponsor model and making any one of the following changes: 
 Decreasing the LOS for Urolift from 0.5 days to 0.25 days 
 Including operating theatre overheads 
 Additional band 5 nurse for BiTURP 
 The cost of a Urolift implant decreases from £330 to below £320 
Urolift becomes cost saving compared with HoLEP in the following circumstances, accepting 
the sponsor model and making one change: 
 The cost of a Urolift implant decreases from £330 to £225 or below 
 
5 Conclusions 
Overall, the studies used in the sponsor’s submission show that Urolift is a clinically effective 
device for the treatment of BPH, giving IPSS score improvements from baseline greater than 
that deemed a “marked improvement” by the original developers of the IPSS score (Barry et 
al. 1995). However, the scope of this assessment called for comparative studies with Urolift 
versus TURP or HoLEP, and none such publications currently exist. In order to provide 
comparative context, the EAC used before-and-after data from papers selected by a recent 
TURP vs. HoLEP systematic review (Li et al. 2014). This pragmatic comparison shows that 
Urolift is out-performed by TURP and HoLEP in terms of IPSS, QoL and Qmax improvements 
from baseline, in patients with similar baseline characteristics. 
However, Urolift appears to have the advantage in terms of minimal and mild complications, 
and this may be of great interest to certain patients and urologists. The clinical evidence 
shows that Urolift is associated with slight improvements in sexual function, and although 
not statistically significant, it certainly does not adversely affect these outcomes. The EAC’s 
comparative exercise for TURP and HoLEP show that sexual function is not well reported in 
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many TURP and HoLEP RCTs (their main focus is IPSS and urological improvements), and this 
led to consultation of the clinical experts. The experts agreed on a 5% erectile dysfunction 
rate and 70-80% retrograde ejaculation rate post-TURP and HoLEP. The most serious of the 
TURP and HoLEP-related complications, are either not possible with Urolift (TUR syndrome) 
or not a risk due to the nature of the Urolift procedure (blood transfusion). The evidence 
may support Urolift being used an  alternative, based upon patient preference, for symptom 
relief lower than that of TURP or HoLEP, but at reduced risk of the more dangerous 
complications. 
The economic case for Urolift was made using a very detailed and thorough de novo cost 
model. Inputs to the model were well-researched and relied upon a robust HTA for TURP 
and HoLEP comparator and cost data (Laurenco et al. 2008) as well as Urolift outcome data 
from the LIFT Study. The model also had a lot of irrelevant data, such as results for TUVP, 
which was outside of the NICE scope for this assessment. 
The base case posed by the sponsor placed Urolift at almost cost-neutral (£3 cost incurring) 
compared to TURP and £418 cost incurring compared to HoLEP. Sensitivity analysis showed 
that the key drivers of the model were the cost of the Urolift device and length of stay post-
procedure. It was difficult to overcome the initial cost of the Urolift implants, even with the 
length of stay and complications savings made post-procedure. The EAC identified a number 
of conditions which changed the sponsor’s model result for Urolift from cost incurring to 
cost saving for each comparator. Against HoLEP, Urolift was only cost saving if the price of 
the Urolift implants was reduced to less than £225. 
The EAC present a scenario in which Urolift can be cost-saving compared to TURP, but not 
HoLEP. This relies upon a low number of Urolift implants, a short procedure time of 30 
minutes or less, adding urological operating theatre overhead costs, local anaesthetic, and a 
day-case procedure of 0.125 days (3 hours). Under these conditions, savings of £336 
compared with mTURP and £209 compared with BiTURP are achievable.  All of the inputs of 
the EAC scenario are supported by published sources or by clinical experts for the 
assessment, who are currently using the Urolift device in the UK. 
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6 Implications for research 
There is currently no published data directly comparing Urolift with TURP or HoLEP, as 
specified in the scope of this assessment. The logical response would be to suggest a truly 
comparative, preferably randomised, two- armed trial with at least one of these comparator 
technologies, or a three-armed trial with both TURP and HoLEP as comparators. This would 
ensure a single, defined patient population and eliminate baseline characteristics 
differences. Collecting resource use data as part of this trial would also strengthen the 
economic data available for decision makers regarding Urolift. 
The BPH-6 trial, currently active but not recruiting, will go some way to addressing this 
research need. Although it only uses TURP as a comparator to Urolift, TURP is the most 
common surgical treatment for BPH in the UK, so this is arguably the most important 
comparison to make. The EAC contacted the sponsor and one of the PIs for BPH-6 (who is 
also a clinical expert for this assessment) and were assured that preliminary data from this 
study would be available in March 2015. It may be possible to update this report, or supply 
an additional data sheet, when these results become available. 
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Appendix 
Appendix 1: EAC literature search strategies 
Example: Ovid MEDLINE(R) search 
1) Prostatic Hyperplasia/ 
2)  Urethral obstruction/ or urinary bladder neck obstruction/ 
3) Lower Urinary Tract Symptoms 
4) LUTS.tw 
5) (urin* adj3 tract* adj3 (sympt* or block*)).tw 
6) ((urin* or urethra*) adj3 (obstruct* or block*)).tw 
7) (Prostat* adj3 Hyperplas*).tw 
8) (prostat* adj3 hypertroph*).tw 
9) (prostat* adj3 adenoma*).tw 
10) Prostatism/ 
11) Prostatism.tw 
12) or/1-11 
13) urolift.tw 
14) Urologic Surgical Procedures, Male/ 
15) (urethra* adj3 lift*).tw 
16) Prostat* adj3 lift*.tw 
17) or/13-16 
18) 12 and 17 
19) Animals/ not humans/ exp animals/ not humans.sh. 
20) 18 not 19 
All other database searches were adaptations of the above. 
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Appendix 2: Urolift results with 95% CIs 
The EAC-calculated weighted means for outcome measure results are shown in section 3.9.1 (Table 
7 –Table 15). Below we present 95% CIs alongside weighted means, although it is only possible to 
present 95% CIs where SDs are reported. Due to inconsistent reporting of SDs in the studies, there 
are far fewer studies included than in the main results presented by the EAC in section 3.9.1. These 
results were calculated using RevMan v5.3 using the general inverse variance option. The confidence 
intervals account for heterogeneity, where significant, using a random effects analysis. 
IPSS 
 
IPSS change from baseline 1 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 53 -10.9 6.9 -10.90 [-12.76, -9.04] 
LIFT Study 138 -9.91 7.08 -9.91 [-11.09, -8.73] 
Shore 2014 51 -10.47 7.35 -10.47 [-12.49, -8.45] 
     
Total 
   
-10.25 [-11.14, -9.36] 
     
 
IPSS change from baseline 3 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 52 -11.1 7.2 -11.10 [-13.06, -9.14] 
LIFT Study 139 -11.13 7.68 -11.13 [-12.41, -9.85] 
Woo 2011 15 -11.2 5.7 -11.20 [-14.08, -8.32] 
     
Total 
   
-11.13 [-12.13, -10.13] 
     
 
IPSS change from baseline 12 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 48 -8.7 7.5 -8.70 [-10.82, -6.58] 
LIFT Study 126 -10.63 7.44 -10.63 [-11.93, -9.33] 
Woo 2011 13 -8.6 7.8 -8.60 [-12.84, -4.36] 
     
Total 
   
-9.80 [-11.23, -8.37] 
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IPSS change from baseline 24 month 
 
Study n Mean SD Mean (95% CI) 
LIFT Study 106 -9.22 7.57 -9.22 [-10.66, -7.78] 
     
 
IPSS QoL 
 
IPSS QoL change from baseline 1 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 53 -2.2 1.8 -2.20 [-2.68, -1.72] 
LIFT Study 138 -2.01 1.74 -2.01 [-2.30, -1.72] 
Shore 2014 51 -2.12 1.94 -2.12 [-2.65, -1.59] 
     
Total 
   
-2.07 [-2.30, -1.85] 
     
 
IPSS QoL change from baseline 3 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 52 -2.3 1.7 -2.30 [-2.76, -1.84] 
LIFT Study 139 -2.22 1.78 -2.22 [-2.52, -1.92] 
Woo 2011 15 -2.8 1.7 -2.80 [-3.66, -1.94] 
     
Total 
   
-2.29 [-2.53, -2.05] 
     
 
IPSS QoL change from baseline 12 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 48 -2 1.7 -2.00 [-2.48, -1.52] 
LIFT Study 126 -2.3 1.59 -2.30 [-2.58, -2.02] 
Woo 2011 13 -2.2 1.9 -2.20 [-3.23, -1.17] 
     
Total 
   
-2.22 [-2.46, -1.99] 
     
 
IPSS QoL change from baseline 24 month 
 
Study n Mean SD Mean (95% CI) 
LIFT Study 106 -2.22 1.71 -2.22 [-2.55, -1.89] 
     
Total 
   
-2.22 [-2.55, -1.89] 
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BPHII 
 
BPHII change from baseline 1 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 53 -3.1 3.3 -3.10 [-3.99, -2.21] 
LIFT Study 138 -2.81 3.46 -2.81 [-3.39, -2.23] 
Shore 2014 51 -3.41 3.57 -3.41 [-4.39, -2.43] 
     
Total 
   
-3.00 [-3.43, -2.56] 
     
 
BPHII change from baseline 3 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 52 -3.3 2.9 -3.30 [-4.09, -2.51] 
LIFT Study 139 -3.96 3.21 -3.96 [-4.49, -3.43] 
     
Total 
   
-3.70 [-4.33, -3.06] 
     
 
BPHII change from baseline 12 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 48 -3.1 3.1 -3.10 [-3.98, -2.22] 
LIFT Study 126 -3.97 3.26 -3.97 [-4.54, -3.40] 
     
Total 
   
-3.60 [-4.44, -2.76] 
     
 
BPHII change from baseline 24 month 
 
Study n Mean SD Mean (95% CI) 
LIFT Study 106 -3.76 3.45 -3.76 [-4.42, -3.10] 
     
Total 
   
-3.76 [-4.42, -3.10] 
 
IIEF 
 
IIEF change from baseline 1 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 34 0.5 4.6 0.50 [-1.05, 2.05] 
Shore 2014 34 0.35 4.76 0.35 [-1.25, 1.95] 
     
Total 
   
0.43 [-0.68, 1.54] 
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IIEF change from baseline 3 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 40 0.7 9.2 0.70 [-2.15, 3.55] 
     
Total 
   
0.70 [-2.15, 3.55] 
 
     
 
IIEF change from baseline 12 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 33 0.9 5.7 0.90 [-1.04, 2.84] 
     
Total 
   
0.90 [-1.04, 2.84] 
 
MSHQ-EjD 
 
MSHQ-EjD change from baseline 1 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 34 1.4 2.3 1.40 [0.63, 2.17] 
Shore 2014 34 1.59 2.75 1.59 [0.67, 2.51] 
     
Total 
   
1.48 [0.89, 2.07] 
     
 
MSHQ-EjD change from baseline 3 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 39 0.7 4.6 0.70 [-0.74, 2.14] 
     
Total 
   
0.70 [-0.74, 2.14] 
     
 
MSHQ-EjD change from baseline 12 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 33 0.8 2.8 0.80 [-0.16, 1.76] 
     
Total 
   
0.80 [-0.16, 1.76] 
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MSHQ-Bother 
 
MSHQ-Bother change from baseline 1 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 34 -0.5 1.1 -0.50 [-0.87, -0.13] 
Shore 2014 34 -0.76 1.39 -0.76 [-1.23, -0.29] 
     
Total 
   
-0.60 [-0.89, -0.31] 
     
 
MSHQ-Bother change from baseline 3 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 37 -0.4 2.3 -0.40 [-1.14, 0.34] 
     
Total 
   
-0.40 [-1.14, 0.34] 
 
     
 
MSHQ-Bother change from baseline 12 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 33 -0.4 1.4 -0.40 [-0.88, 0.08] 
     
Total 
   
-0.40 [-0.88, 0.08] 
 
Qmax 
 
Qmax change from baseline 1 month 
 
Study n Mean SD Mean (95% CI) 
Shore 2014 50 3.3 4.5 3.30 [2.05, 4.55] 
     
Total 
   
3.30 [2.05, 4.55] 
     
 
Qmax change from baseline 3 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 40 2.5 5.3 2.50 [0.86, 4.14] 
LIFT Study 124 4.24 5.13 4.24 [3.34, 5.14] 
     
Total 
   
3.51 [1.83, 5.19] 
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Qmax change from baseline 12 month 
 
Study n Mean SD Mean (95% CI) 
Cantwell 2013 37 2.5 5 2.50 [0.89, 4.11] 
LIFT Study 105 3.98 4.92 3.98 [3.04, 4.92] 
     
Total 
   
3.39 [1.97, 4.81] 
     
 
Qmax change from baseline 24 month 
 
Study n Mean SD Mean (95% CI) 
LIFT Study 98 4.15 5.05 4.15 [3.15, 5.15] 
     
Total 
   
4.15 [3.15, 5.15] 
 
PVR 
No SDs reported for PVR results, therefore it was not possible to calculate 95% CIs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 109 of 111 
 
MT241 Urolift 
Urolift Assessment Report 
Appendix 3: Critical appraisal of Li et al. (2014) 
Support Unit for Research Evidence (SURE) Questions to assist with the critical 
appraisal of a systematic review1 
 
This work is licensed under the Creative Commons Attribution - NonCommercial-ShareAlike 3.0 Unported License. To 
view a copy of this license visit http://creativecommons.org/licenses/by-nc-sa/3.0/  
 
Citation:  Li 2014 
Registered on Prospero 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014007334 
 
Questions ** relate to whether the methodology used is described – eg independently in duplicate 
 
1.   Does the review address a clearly focused 
question/hypothesis 
Yes 
 
Can't tell 
 
No 
Population/Problem? Yes 
Intervention? Yes 
Comparator/control? Yes 
Outcomes? 
Can you identify the primary outcome? 
Yes 
2.   Did the authors look for the appropriate 
types of paper? 
Did the studies address the review's question and have 
an appropriate design?  
 
Yes 
3.  Is the search likely to have identified all the 
relevant evidence? 
Yes generally ok but no search for clinical 
trials or manufacturer contact 
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Sufficient range of databases searched? 
Date range appropriate?   
Good range of search terms (indexed terms and 
keywords) 
 
Reference list/bibliography checking?  
Hand search (journals)  
 Grey literature searched (unpublished work) 
Websites? 
Contacting experts/manufacturers? 
 
Search terms/ strategy provided? 
Were they comprehensive? 
 
Search results provided (no of hits and final 
studies)? 
Flow diagram? 
 
All languages included?  
4. Are all relevant studies likely to have been 
included? 
Yes 
Are the inclusion and exclusion criteria stated?  
Is the study selection process described? **  
Multiple papers relating to same study identified?  
Is the data extraction process described? **  
5.  Did the authors assess the quality (rigour) 
of the included studies? 
Yes 
Is the assessment process described? ** 
 
 
6.   Information about included studies 
 Is key information provided (eg study design, 
population, interventions, comparators, outcomes, 
Yes 
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areas of potential bias)? 
7.   If the results of the review have been 
combined (meta-analysis), was this 
appropriate? 
Yes 
Were the studies sufficiently similar in design and 
results? 
 
Are the reasons for any variations discussed?  
8.   Are results provided for all included 
studies? 
 Do the conclusions reflect all results?  
 Is the quality assessment of individual studies 
reflected in the results? 
Yes  
9.  Were all the important outcomes 
considered? 
Yes 
10.  Is any sponsorship/conflict of interest 
reported? 
None 
11.  Finally…consider:  
Did the authors identify any limitations? 
Date of review – is it likely to be out of date? 
Are the conclusions the same in the abstract and 
the full text? 
Ok 
 
This checklist should be cited as:  
Support Unit for Research Evidence (SURE) 2013. Questions to assist with the critical appraisal of a systematic 
review. Available at: http://www.cardiff.ac.uk/insrv/libraries/sure/doc/SURE_RCT_Checklist_2013.pdf  
1 Adapted and updated from the former Health Evidence Bulletins Wales (HEBW) checklist with reference to the NICE Public 
Health Methods Manual (2012) and previous versions of the Critical Appraisal Skills Programme (CASP) checklists.  
 
 
